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Dear Colleague:
The Diabetes Prevention and Control Program of the Massachusetts Department of Public Health and members of the
Diabetes Guidelines Work Group are pleased to present the latest update to the Massachusetts Guidelines for Adult Diabetes
Care, based on the American Diabetes Association’s 2009 Clinical Practice Recommendations. First created in 1999, the
Guidelines are revised every two years. Our initial goals were to: 1) develop uniform guidelines that apply to adults with
diabetes regardless of insurer; 2) help eliminate any confusion brought about by differences in guidelines disseminated by
individual third party payers; and 3) assist health care professionals in systematizing the care provided to people with diabetes.
Many organizations worked together to create and update this document. We hope that it is user-friendly and will serve as a
valuable tool to improve diabetes care in the Commonwealth.
Revisions
The 2009 changes to the Guidelines include:
• Revised target threshold for preprandial glucose and new Estimated Average Glucose (eAG) table
• Revised recommendations for screening prior to starting an exercise program
• Updated Algorithm for the Metabolic Management of Type 2 Diabetes
• New Summary of Glucose-Lowering Interventions table
• Updated medication tables (moved to Appendix A)
• Revised recommendations for management of cardiovascular disease
• Revised LDL Cholesterol-Lowering Decision Tree algorithm
• New Stages of Kidney Disease table
• Updated Tobacco Use and Diabetes section
• New Immunizations section
• Updated Inpatient Glucose Control section
Partners
The Guidelines are a collaborative effort among many partners:
Additional Information
• The Guidelines are available online at www.mass.gov/dph/diabetes
• You may also order copies of the Diabetes Care Cards and the laminated Guidelines Summary free of charge from the Massachusetts Health
Promotion Clearinghouse at www.maclearinghouse.com or via the order form.
• If you have questions about the Guidelines, please call the Massachusetts Diabetes Prevention and Control Program at (617) 624-5070.
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1
INTRODUCTION
Both national studies and state data indicate that people with diabetes do not receive recommended levels of preventive care,
leaving wide gaps between current recommendations and actual practice. The Massachusetts Guidelines for Adult Diabetes Care were
developed as a way to improve diabetes care in the Commonwealth. TheGuidelines highlight and summarize essential components
of quality diabetes management, and offer accompanying tools for use in the primary care setting. These Guidelines are neither
intended to replace the clinical judgment of primary care providers, nor are they intended to preclude more extensive evaluation
and management of the patient by other specialists as needed.
The Guidelines are developed by a Work Group convened by the Massachusetts Department of Public Health’s Diabetes
Prevention and Control Program and its Advisory Board. The Work Group is comprised of clinicians, representatives from man-
aged care organizations, the Primary Care Clinician Plan, Joslin Diabetes Center, the Massachusetts College of Pharmacy and
Health Sciences, the Massachusetts League of Community Health Centers, the Massachusetts Medical Society, MassPRO, and the
University of Massachusetts Amherst. First developed in 1999, the Guidelines are based on the American Diabetes Association’s
(ADA) Clinical Practice Recommendations, and are reviewed and revised by the Work Group every two years.
The Guidelines are a cooperative effort among many partners. This unique collaboration eliminates the confusion brought about
by slight differences in guidelines developed by each managed care organization. The Guidelines are not intended to serve as a
description of benefits or coverage; coverage may vary by insurer.
The 2009 Guidelines have been updated and include statements on:
• Screening and diagnosing diabetes and pre-diabetes
• Lifestyle intervention and/or pharmacological treatment for IFG and IGT
• New target threshold for preprandial plasma glucose
• Estimated average glucose
• Physical activity and resistance training
• Management of hyperglycemia in individuals with type 2 diabetes
• Cardiovascular treatment recommendations and goals
• Stages of kidney disease
• Medications to treat symptomatic distal polyneuropathy
• Immunizations
• Inpatient glucose management
We have also added a grading system developed by the ADA and updated the Commonly Used Oral Antidiabetic Agents
tables (now in Appendix A).
In addition to the 2009 Guidelines, the following tools are available:
Guidelines for Adult Diabetes Care
(laminated summary)
This summary of the Guidelines highlights basic medical care for
people with diabetes. We suggest you post them in each exam room
as a reminder of recommendations for care.
Determining Body Mass Index (BMI)
Obesity substantially raises the risk of morbidity from type 2
diabetes and other diseases. The BMI describes relative weight for
height and is significantly correlated with total body fat content.
The BMI may be used to assess overweight and obesity and to
monitor changes in body weight.
Flow Sheet for Diabetes Care
The flow sheet reflects the recommendations found on the
Guidelines for Adult Diabetes Care laminated summary. It can be
copied or modified for use in your practice and included in
patients’ charts. Diabetes medications, exams, and test results can
be documented over time to track diabetes management.
Diabetes Care Card (patient wallet card)
The Diabetes Care Card allows people with diabetes to track their
diabetes care and personal goals. The wallet card has space to record
test results and services received over four visits. Encourage your
patients to bring this card to each office visit.
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The Massachusetts Guidelines for Adult Diabetes Care are based on the Clinical Practice Recommendations of the ADA. A grading system
developed by the ADA was utilized for the recommendations. The level of supportive evidence is noted in parentheses after each recom-
mendation using the letters A, B, C, or E.
(A): Clear evidence from well-conducted, generalizable, randomized controlled trials.
(B): Supportive evidence from well-conducted cohort studies.
(C): Supportive evidence from poorly controlled or uncontrolled studies.
(E): Expert consensus or clinical experience.
Recommendations with an “A” rating are based on large well-designed clinical trials or well-done meta-analyses. Generally, these
recommendations have the best chance of improving outcomes when applied to the population for which they are appropriate.
Recommendations with lower levels of evidence may be equally important but are not as well supported. Expert opinion (E) is a separate
category for recommendations for which there is as yet no evidence from clinical trials, for which clinical trials may be impractical, or for
which there is conflicting evidence.1
GRADING OF EVIDENCE
1American Diabetes Association. Clinical Practice Recommendations. Introduction. Diabetes Care 32, S1-S2, 2009.
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DIAGNOSIS OF DIABETES MELLITUS AND PRE-DIABETES
Criteria for Testing for Diabetes and Pre-diabetes in Asymptomatic Adults
Testing for diabetes should be considered for all individuals aged 45 and older. Testing should be considered at a younger age in
individuals who are overweight (BMI ≥ 25kg/m2 or BMI ≥ 23 kg/m2 for Asian individuals)2 and with any of the additional risk factors:3
• Habitually physically inactive
• First-degree relative with type 2 diabetes
• Members of a high-risk ethnic population (African American, Latino, Native American, Asian American, Pacific Islander)
• Delivered a baby weighing > 9 lbs. or have been diagnosed with Gestational Diabetes Mellitus (GDM)
• Hypertensive ( ≥ 140/90 mmHg, or on therapy for hypertension)
• High-density lipoprotein (HDL) cholesterol level ≤ 35 mg/dl and/or a triglyceride level ≥ 250 mg/dl
• Polycystic ovarian syndrome (PCOS)
• Impaired Glucose Tolerance (IGT) or Impaired Fasting Glucose (IFG) on previous testing
• Other conditions associated with insulin resistance (acanthosis nigracans)
• History of vascular disease
• A waist circumference > 102 cm (40”) for men and > 88 cm (35”) for women4
• Medication use that may predispose to diabetes (e.g., steroids, atypical antipsychotics, protease inhibitors)
If normal, testing should be repeated at three-year intervals, with consideration of more frequent testing depending on initial results and
risk status.
Criteria for the Diagnosis of Diabetes and Pre-diabetes in Nonpregnant Adults
In the absence of unequivocal hyperglycemia, these criteria should be confirmed by repeat testing on a different day.
Fasting Plasma Glucose Casual Plasma Glucose Oral Glucose Tolerance Test
(FPG)* (preferred) (CPG)** (OGTT)***
Diabetes Mellitus FPG ≥ 126 mg/dl Casual Plasma Glucose Two-hour plasma glucose
≥ 200 mg/dl (2-h PG) ≥ 200 mg/dl
plus symptoms of diabetes
Pre-diabetes Impaired Fasting Glucose (IFG) Impaired Glucose Tolerance
FPG ≥ 100 and < 126 mg/dl (IGT)
2-h PG ≥ 140 and < 200 mg/dl
Normal FPG < 100 mg/dl 2-h PG < 140 mg/dl
* A FPG via venipuncture is the preferred diagnostic test due to its ease of administration, convenience, acceptability to patients, and lower cost. Fasting is
defined as no caloric intake for at least 8 hours.
** Casual is defined as any time of day without regard to time since last meal. Symptoms are the classic ones of polyuria, polydipsia, and unexplained weight
loss. There are currently no guidelines for interpreting CPG values that fall between 140-199 mg/dl. For values in this range, options include routine moni-
toring of FBGs or alternatively, testing with OGTT.
*** OGTT should be performed using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water. The OGTT is not recom-
mended for routine clinical use, but may be necessary when evaluating patients with IFG or when diabetes is still suspected despite an FPG < 126 mg/dl.
The term A1C is used to represent tests of average glycemic control such as glycosylated or glycated hemoglobin (HbA1c). The A1C test
measures average blood glucose over the preceding 2 to 3 months and is used to monitor glucose control in patients with diabetes. The test
should be performed in all patients with diabetes at initial assessment and then routinely as part of continuing care. The A1C test can be
performed non-fasting, without regard to time since last meal.
An International Expert Committee has recently proposed that hemoglobin A1c (A1C) assays be considered as the principal means of
screening and diagnosing type 2 diabetes, essentially replacing fasting blood glucose (FBG) and the oral glucose tolerance test (OGTT). At
the time of this printing, however, the criteria for diagnosing diabetes remain as listed.
2National Obesity Forum,Weisell R.Body mass index as indicator of obesity. Asia Pac J Clin Nutri: 11(Supplement 8):S681-S684, 2002. http://www.nationalobesityforum.org.uk
3American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 32 (Supplement 1):S13-S61, 2009.
4Balkau B, et al.Waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation 116:1942-1951, 2007.
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Not all classifications of diabetes are discussed here. For further information on other types, see the ADA reference below.5
Type 1
Type 1 diabetes most often results from a cellular mediated autoimmune destruction of the beta cells of the pancreas. Patients with this
form of diabetes are dependent upon insulin for survival and are at risk for ketoacidosis. Type 1 diabetes commonly presents in childhood
and adolescence but may present at any age.
Type 2
Individuals with type 2 diabetes have insulin resistance and relative insulin deficiency. Over time, the potential for absolute deficiency
exists. Primary treatment centers on beta cell preservation and improving insulin resistance via weight loss, improved nutrition, and
increased age-appropriate physical activity. Type 2 diabetes commonly goes undiagnosed for years because it is often asymptomatic in its
early stages. Individuals with undiagnosed type 2 diabetes are at increased risk for developing macro- and microvascular complications.
Gestational Diabetes Mellitus (GDM)
GDM, which typically occurs following the 24th week of pregnancy, is defined as any degree of glucose intolerance with onset or first
recognition during pregnancy. It does not exclude the possibility that unrecognized glucose intolerance may have preceded, or begun
concomitantly with the pregnancy. Six weeks or more after the pregnancy ends, a woman with GDM should be tested to rule out
type 1 or type 2 diabetes or pre-diabetes. Women with GDM and their children have a higher risk for development of type 2 diabetes later
in life.
Pre-diabetes
Both Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) have been categorized as pre-diabetes and are risk factors for
future diabetes and cardiovascular disease. IFG has been defined as a fasting plasma glucose of ≥100 mg/dl but < 126 mg/dl. IGT is
defined as a 2-hour oral glucose tolerance test (OGTT) value of ≥ 140 mg/dl, but < 200 mg/dl.
4
5American Diabetes Association (Position Statement). Diagnosis and classification of diabetes mellitus. Diabetes Care 32 (Supplement 1):S62-S67, 2009.
PREVENTION OR DELAY OF TYPE 2 DIABETES
Massachusetts Guidelines for Adult Diabetes Care • Revised June 2009
Diabetes Prevention and Control Program Diabetes Guidelines Work Group
Summary
Hyperglycemia that does not meet the diagnostic criteria for diabetes is referred to as Impaired Fasting Glucose (IFG) or Impaired Glucose
Tolerance (IGT) and officially termed pre-diabetes.
Several well-designed studies have shown that individuals at high risk for developing type 2 diabetes can be given lifestyle modification
interventions that significantly delay or prevent the onset of diabetes.6 The Diabetes Prevention Program (DPP) was a randomized clinical
trial conducted in 27 sites across the United States. DPP results showed that lifestyle intervention was nearly twice as effective as a glucose-
lowering medication (metformin) in delaying or preventing the onset of diabetes in individuals at risk.7 Study populations often had other
recognized risk factors for diabetes including obesity, a prior history of gestational diabetes, or a positive family history of diabetes.8
These studies have shown that modest weight loss (5-10% of body weight) and regular physical activity can reduce the rate of progression
of IGT to type 2 diabetes. The following lifestyle modifications should be the first treatment modality to employ in persons at high risk:
• Reduced-calorie, reduced-fat meal planning
• Increased moderate-intensity physical activity
Such interventions also provide a variety of other health benefits in addition to delaying diabetes. At every opportunity, health care
providers are encouraged to stress the benefits of weight loss and physical activity for overweight or sedentary patients.
Recommendations:
• Patients with IGT (A) or IFG (E) should be referred to an effective ongoing support program for weight loss of 5-10% of body weight
and for increasing physical activity to at least 150 minutes per week of moderate activity such as walking.
• In addition to lifestyle counseling, metformin may be considered in those individuals at very high risk of developing diabetes. (E)
5
6American Diabetes Association (Position Statement). Diagnosis and classification of diabetes mellitus. Diabetes Care 32 (Supplement 1):S62-S67, 2009.
7Diabetes Prevention Program (DPP): Knowler WC, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med
346:393-403, 2002.
8Nathan DM, et al. Consensus statement. Impaired fasting glucose and impaired glucose tolerance. Implications for care. Diabetes Care 30:753-759, 2007.
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* Some providers may use A1C to monitor for progression to diabetes.
**Recommended dosing for metformin: 500-850 mg twice per day, based on gastrointestinal tolerance.
Recent trials have evaluated the use of medications, such as metformin and thiazolidinediones (TZDs), to address insulin resistance in
delaying or preventing the development of type 2 diabetes. Given current cost estimates, use of insulin sensitizer medications such as met-
formin as a first line of defense should be given consideration, contraindications not withstanding. Some of the manufacturers of thiazo-
lidinediones have reported observational data of an increased risk of fractures (arm, hand, and ankle and foot of 9.30%, 5.09%, and
3.47% respectively) as compared to metformin and glyburide in women taking these agents for three or more years.10,11 See Commonly
Used Antidiabetic Medications in Appendix A for additional information on these medications.
PREVENTION OR DELAY OF TYPE 2 DIABETES
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Treatment Recommendations for Individuals with IFG, IGT, or Both9
Population
IFG or IGT
Individuals with IFG and IGT and any of the following:
• < 60 years of age
• BMI ≥ 35 kg/m2
• Family history of diabetes in first-degree relatives
• Elevated triglycerides
• Reduced HDL cholesterol
• Hypertension
• A1C > 6.0%*
9Nathan DM, et al. Consensus statement. Impaired fasting glucose and impaired glucose tolerance. Implications for care. Diabetes Care 30:753-759, 2007.
10The U.S. Food and Drug Administration, http://www.fda.gov/medwatch/safety/2007/Avandia_GSK_Ltr.pdf
11The U.S. Food and Drug Administration, http://www.fda.gov/medwatch/safety/2007/safety07.htm#Actos
Treatment
Lifestyle modification (i.e., 5–10% weight loss and moderate
intensity physical activity of at least 150 minutes/week or
30 minutes each day, 5 times per week)
Lifestyle modification (as above) and consider the addition of
metformin**
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Treatment Goals
Optimal treatment for type 2 diabetes incorporates a multiple risk factor approach, including self-management education and ongoing
support, medical nutrition therapy (MNT), physical activity, weight reduction if appropriate, and the use of glucose-lowering oral agents
or insulin. Careful consideration needs to be given to ameliorating associated risk factors such as hypertension, smoking, and dyslipidemia.
When possible, care should be provided by a coordinated team that may include physicians, nurse practitioners, physician assistants, dia-
betes educators, community health workers, nurses, dietitians, pharmacists, social workers, and mental health and other professionals with
expertise and special interest in diabetes.
Recommendations:
• Perform the A1C test at least two times a year in patients who are meeting treatment goals and who have stable glycemic control. (E)
• Perform the A1C test quarterly in patients whose therapy has changed or who are not meeting glycemic goals. (E)
• Having lab results available at the time of the visit is advantageous and may allow for timely decisions on therapy changes. (E) The use of
point-of-care testing may facilitate this process. However, as with all point-of-care testing, accuracy may be equipment- and user-dependent.
When setting treatment goals for individuals with type 2 diabetes, it is important to assess the risk for severe hypoglycemia and consider
the person’s ability to comprehend the regimen. Consider as well other factors that may influence the treatment’s benefit, including
advanced age, end-stage renal disease (ESRD), advanced cardiovascular or cerebrovascular disease, or other comorbidities that may lead to
reduced life span.
Both the A1C test and patient self-monitoring of blood glucose (SMBG) may be used to assess effectiveness of the management plan on
glycemic control. Achievement of desired glucose targets requires education in self-management techniques, including:
• SMBG
• Recognition, treatment, and prevention of hypoglycemia
• Prevention, early detection, and treatment of chronic complications
• MNT (see page 12 for definition and description)
• Regular physical activity
• Reinforcement, continuing education, and ongoing support
Patients with frequent or severe hypoglycemia may require less intensive glycemic goals. Children, pregnant women, and elderly individu-
als require special consideration when setting glycemic goals.
7
* More stringent goals, including a normal A1C of < 6%, can be considered in individual patients and for women who are planning to become pregnant
or who are pregnant. Conversely, less stringent goals may be appropriate depending on age and comorbid conditions.
Goals for Glycemic Control in Nonpregnant Adults*
Normal Goal
Preprandial Plasma Glucose < 100 mg/dl 70-130 mg/dl
Peak Postprandial < 120 mg/dl < 180 mg/dl
(2-hour) Plasma Glucose
A1C < 6% < 7%
TREATMENT APPROACH PRINCIPLES FOR TYPE 2 DIABETES
Clinical trials, such as the Diabetes Control and Complications Trial (DCCT), the United Kingdom Prospective Diabetes Study
(UKPDS), and the microvascular evidence from the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR
Controlled Evaluation) trial suggest a small but incremental benefit in microvascular outcomes with A1C values closer to normal.
Therefore, for selected individual patients, providers might reasonably suggest even lower A1C goals than the general goal of < 7%, if this
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TREATMENT APPROACH PRINCIPLES FOR TYPE 2 DIABETES
12American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 32 (Supplement 1):S13-S61, 2009.
13Stratton IM, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study.
BMJ 321:405-412, 2000.
14Nathan DM, et al. Translating the A1C into estimated average glucose values. Diabetes Care 31:473–1478, 2008.
15American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 32 (Supplement 1):S13-S61, 2009.
16Ibid.
can be achieved without significant hypoglycemia or other adverse effects of treatment. Such patients might include those with short
duration of diabetes and long life expectancy.12
Points to remember when setting glycemic goals:
• Individualize goals based on: duration of diabetes, age/life expectancy, comorbid conditions, known cardiovascular disease (CVD) or
advanced microvascular complications, and hypoglycemia unawareness.
• If preprandial glucose goals are within target, but A1C values are still not optimal, target postprandial glucose.
• A lower A1C is associated with lower rates of microvascular complications; however, there is a greater risk of hypoglycemia.13
• For patients with frequent or severe hypoglycemia, less intensive glycemic control may be preferable.
• Children, pregnant women, and elderly individuals require special consideration when setting glycemic goals.
• Avoid rapid decline in glycemia when prior adverse control was substantial or prolonged.
For those patients who fail to reach target A1C goals after repeated attempts with their primary care providers, an endocrinologist
may be consulted. Patients with recurrent hypoglycemia, hypoglycemia unawareness, or nocturnal hypoglycemia; patients on pump
therapy or continuous glucose monitoring systems (CGMS); or pregnant women and geriatric patients may benefit from consultation with
an endocrinologist.
To assist in improving patients’ understanding of the A1C, the ADA and the American Association of Clinical Chemists have determined
that the correlation between A1C levels and mean plasma glucose levels based on data from the A1C-Derived Average Glucose (ADAG)
trial support the reporting of the measured A1C as estimated average glucose (eAG). The interpretation of the A1C should provide patients
with a more useful index of chronic glycemia. A recently published consensus guideline has endorsed reporting A1C values along with the
calculated eAG level.14,15
To convert A1C to eAG: 28.7 x A1C - 46.7 = eAG (in mg/dl)
A calculator for converting A1C results into eAG, in either mg/dl or mmol/l, is available at:
http://professional.diabetes.org/eAG
Estimated average glucose (eAG)16
A1C (%) Mean plasma glucose (mg/dl)
6 126
7 154
8 183
9 212
10 240
11 269
12 298
XXXX
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Purpose
Diabetes Self-Management Education (DSME) should be offered throughout the life span of those diagnosed with diabetes and
pre-diabetes. Families and support systems are encouraged to participate. The main aims of DSME are to provide patients with the
management skills necessary to achieve optimal control of their diabetes, and to assist them in becoming effective, self-directed decision
makers for their own diabetes care, health, and well-being. Without comprehension of the relationship between blood glucose readings,
meal planning, and physical activity, patients with diabetes will be hindered in their ability to achieve optimal blood glucose control,
and are at higher risk for long-term complications. A referral to a Certified Diabetes Educator (CDE) or clinician who has expertise in
culturally competent DSME is strongly recommended. A CDE may be a nurse, physician, dietitian, social worker, exercise physiologist,
or pharmacist.17
National standards for DSME have been established by the American Diabetes Association (ADA) to define quality diabetes self-
management education that can be implemented in diverse settings and will facilitate improvement in health outcomes. Standards are
reviewed and updated on a regular basis, so the most current standards should be accessed on the ADA website.18
Goals for DSME
• Prevent type 2 diabetes
• Prevent the acute complications of diabetes, hyperglycemia, and hypoglycemia
• Prevent or delay the chronic complications of diabetes
• Promote healthy birth outcomes through preconception counseling, monitoring, and support during and after pregnancy
• Enhance patient participation in the diabetes treatment
• Plan and improve patient confidence in self-management skills
• Enhance psychosocial adjustment to living with a chronic disease
• Decrease health care costs by reducing the need for expensive hospital stays and the treatment of complications
• Maximize quality of life in a cost-effective manner
A referral for a face-to-face educational assessment is recommended. This allows for an appropriate educational treatment plan to be
outlined. DSME is offered at both basic and advanced training levels. Consideration should be given to the patient for dealing with
psychosocial aspects of the diagnosis. Literacy and cultural issues that may impact training should also be evaluated. Advances in treatment
options are continuing. DSME should be offered annually after initial diagnosis. Ongoing training should ensure that patients are current
in changing technology and self-management behavioral strategies.
Assessment of knowledge and needs of individuals with pre-diabetes and diabetes will determine which of the content areas on the follow-
ing page are to be provided.19
9
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17National Certification Board for Diabetes Educators, http://www.ncbde.org
18American Diabetes Association, http://www.diabetes.org
19Funnell MM, et al. National standards for diabetes self-management education. Diabetes Care 32:S87-S94, 2009.
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Diabetes Disease Process
Overview
• Benefits of optimal diabetes control and factors that influence it
• Effects of insulin resistance, deficiency, and excess
• Treatment of insulin resistance through weight loss, physical activity, and medication
• Nature of diabetes in terms of chronicity and metabolism
• Differences between type 1 diabetes, type 2 diabetes, pre-diabetes, and gestational diabetes, if indicated
• Balance of meals, physical activity, and medication, if prescribed
Nutrition
• Basic vs. advanced training (i.e., basic food groups vs. carbohydrate to insulin ratio)
Physical activity
• Impact of physical activity on blood glucose, lipid levels, hypertension, weight, and stress reduction
• Frequency, level, and benefits of physical activity
• Impact of physical activity on hyperglycemia, ketosis, and hypoglycemia
• Physical activity planning appropriate to age, ability, interest, and willingness
• Potential impact of physical activity on long-term diabetes complications and skills for avoiding injury
Medications
Oral Medication Management
• Action, side effects, timing of dose(s), interactions
Insulin Management
• Action, dosage, onset/peak/duration, pre-filling, mixing, injecting, site selection, storage, syringe/needle/lancet disposal, travel
guidelines, adjustments for sick and well days
• Recommendations for syringe reuse: techniques, benefits, and risks
• Pump use, if appropriate
• Use of Glucagon, if appropriate
Injectable medication, if prescribed
• Influences of other medications on blood glucose and possible interactions with oral diabetes and other medications
Monitoring/using results
• Blood glucose meter selection and orientation
• Time(s) to check blood glucose/rationale
• Recording and interpreting results, encouraging dialogue with clinician
• Establish A1C targets
• Use of SMBG to adjust the treatment plan based on approved guidelines
• Disposal of syringes, needles, lancets, and other contaminated materials
• Urinary and blood ketone testing, if appropriate
• Use of advanced technology: Continuous Glucose Monitoring System (CGMS), if appropriate
10
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Acute complications
• Hypoglycemia and hyperglycemia recognition, causes, treatment, and prevention
• Diabetes management during illness
• Trauma, surgery, and/or severe acute illness
• Planning skills for scheduled procedures and surgeries
• Potential changes in blood glucose monitoring
• Meal planning changes: short- and long-term where applicable (e.g., surgeries, illness > 1-2 days)
• Potential changes in medication (e.g., addition of insulin to oral medications or insulin initiation; times and frequency of insulin doses)
• Signs and symptoms of acute changes in status of diabetes control
(e.g., Diabetic Ketoacidosis [DKA], dehydration, Hyperosmolar Hyperglycemic State [HHS])
• Importance of strict glycemic control during:
o Pre-surgical preparation
o Recovery period
Complications prevention and recognition
• Self-foot care, early detection of problems, and importance of timely access to care
• Early recognition of eye disease and need for complete eye exam
• Impact of lipids: importance of monitoring annually, or every two years if values fall within accepted risk levels
• Importance of blood pressure control: need for regular monitoring
• Identification of the symptoms, treatment, and major factors contributing to the development of complications
• Preventing kidney disease, peripheral vascular disease, cardiovascular disease, periodontal disease, and neuropathy
• Importance of pneumonia vaccine and yearly flu vaccine
• Smoking cessation
• Use of aspirin if not contraindicated
Goal setting and problem solving
Psychosocial adjustment
• Assess adjustment to lifestyle changes; screen for depression, eating disorders, and cognitive impairment; refer to counseling as needed
• Develop psychosocial skills and incorporate into routine care to support emotional well-being
• Ongoing support
Preconception care, pregnancy, and gestational diabetes (GDM)
Women who are pregnant and have diabetes, whether preexisting or GDM, have a goal of delivering a healthy baby after gestation. In
order to accomplish this goal, it is critical for the mother’s glucose levels to be within the target range, before pregnancy for those with
preexisting diabetes and during pregnancy for all women. The treatment plan will include MNT, as well as physical activity and insulin as
needed. The treatment plan will need to be adjusted throughout the course of the pregnancy and frequent monitoring will be required.20
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Summary
Medical nutrition therapy (MNT), defined as nutritional diagnostic, therapeutic, and counseling services provided by a registered
dietitian or nutrition professional for the purpose of managing diabetes, is an integral component of assisting patients in acquiring and
maintaining the knowledge, skills, and behaviors to successfully meet the challenges of daily diabetes self-management.21
The 2006 Nutrition Recommendations and Interventions for Diabetes, published by the ADA, identifies three categories of MNT:
primary prevention to reduce the risk of, or delay the onset of, diabetes; nutrition management for blood glucose control; and manage-
ment and prevention in the treatment of comorbidities.22 Adequate nutrition advice or an individualized meal plan will assist patients
in achieving optimal blood glucose control. Meeting nutrition-related goals requires a coordinated team effort that includes the person
with diabetes. A referral to a registered dietitian skilled in the complexities of diabetes management is strongly recommended.
Recommendations:
• People with pre-diabetes or diabetes should receive individualized MNT as needed to achieve treatment goals, preferably provided by
a registered dietitian familiar with components of diabetes MNT. (B)
• Weight loss is recommended for all overweight or obese individuals who have or are at risk for diabetes. (A)
• For weight loss, either low-carbohydrate or low-fat, calorie-restricted diets may be effective in the short-term (up to 1 year). (A)
• For patients on low-carbohydrate diets, monitor lipid profiles, renal function, and protein intake (in those with nephropathy) and
adjust hypoglycemic therapy as needed. (E)23
Motivational interviewing, a counseling technique shown to be beneficial in behavioral change, should be utilized in working with
clients to modify nutritional intake.24,25
Goals for MNT
• Achieve and maintain near normal blood glucose levels as well as optimal lipid levels, blood pressure, and recommended body weight.
• Prevent and treat the acute and long-term complications of diabetes.
• Improve overall health through optimum nutrition and physical activity.
• Address individual needs, considering cultural preferences, lifestyle, and ability to change.
• Maintain the pleasure of eating by only limiting food choices when indicated by scientific evidence.
• Delay the onset of diabetes in patients with pre-diabetes.
• Provide for the needs of special populations:
o Youth with type 1 or type 2 diabetes
o Pregnant and lactating women
o Older adults
o Active individuals treated with drugs that may potentially cause hypoglycemia (insulin and insulin secretagogues and
meglitinides) to ensure safety during activity
o Individuals at risk for developing diabetes
o Individuals with deteriorating renal or cardiac function
o Individuals with deteriorating visual acuity
12
21Centers for Medicare and Medicaid Services. Medical nutrition therapy services: overview. http://www.cms.hhs.gov/medicalnutritiontherapy
22American Diabetes Association (Position Statement). Nutrition recommendations and interventions for diabetes. Diabetes Care 31:S61-S78, 2008.
23American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 32 (Supplement 1):S13-S61, 2009.
24West DS, et al. Motivational interviewing improves weight loss in women with type 2 diabetes. Diabetes Care 30:1081-1087, 2007.
25Channon SJ, et al. A multicenter randomized controlled trial of motivational interviewing in teenagers with diabetes. Diabetes Care 30:1390-1395, 2007.
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Basic Education
For patients newly diagnosed with diabetes or pre-diabetes, or patients not recently educated, basic survival skills should include:
• Relationship of food and meals to blood glucose levels, medication, and physical activity
• Monitoring of total grams of carbohydrate intake
• Basic food/meal plan guidelines, including portion control
• Consistent times each day for meals and snacks
• Recognition, prevention, and treatment of hypoglycemia
• Diabetes management during illness
• Self-monitoring of blood glucose
Advanced MNT topics should include:
• Weight loss strategies, including reduction in energy intake and/or increase in physical activity, if indicated; consideration of
medications and/or bariatric surgery for those with a BMI ≥ 35
• Amount (grams) and type of carbohydrate in food and influence on blood glucose levels
• Use of meal replacements, if desired
• Glycemic index
• Sources of nutrients and their effects on blood glucose and lipid levels
• Carbohydrate counting
• Label reading and grocery shopping guidelines
• Dining out
• Reduced dietary energy from saturated fat (< 7% of total energy); intake of trans fat should be minimized
• Use of sugar-containing foods, dietetic foods, and sweeteners
o Sugar alcohols and nonnutritive sweeteners are safe when consumed within the acceptable daily intake levels established by
the Food and Drug Administration (FDA)
• Alcohol guidelines
o If adults with diabetes choose to use alcohol, daily intake should be limited to a moderate amount
(one drink per day or less for adult women and two drinks per day or less for adult men)
• Using blood glucose monitoring for glucose pattern control
• Adjusting meal times
• Adjusting food for physical activity
• Special occasions, holidays
• Travel, schedule changes
• Vitamin and mineral supplementation
o Routine supplementation with antioxidants, such as vitamins E and C and carotene, is not advised because of lack of evidence of
efficacy and concern related to long-term safety
o Benefit from chromium supplementation in people with diabetes or obesity has not been conclusively demonstrated,
and therefore cannot be recommended
13
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Ongoing Nutrition Education
Ongoing nutrition education is recommended for patients recently diagnosed with diabetes or pre-diabetes who have been taught basic
survival skills. Patients who may benefit from nutrition education include those who have not received current nutrition education, who
are having difficulty with diabetes management, or who are experiencing changes in lifestyle, medication, weight, or childbearing status.
Follow-up sessions should focus on increasing the patient’s knowledge, skills, and flexibility as he or she gains experience living with diabetes.
A weight loss program should include:
• Individualized counseling
• Structured, intensive lifestyle education
• Promotion of healthy food choices and physical activity
14
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Summary
Physical activity is an important component of a healthy lifestyle that can help to prevent diabetes and its complications. The use of the
term “physical activity” is preferred to “exercise” because it includes the spectrum of options from mild (e.g., walking or light housekeeping)
to moderate (e.g., brisk walking, dancing, swimming, bicycling) to vigorous (e.g., jogging, bicycling uphill, swimming multiple laps).
The metabolic effects of physical activity are generally measurable up to 24-48 hours after a single session. Therefore, repeated sessions of
physical activity (generally 5-7 times per week) are recommended to achieve ongoing benefits.26,27
Recommendations:
• People with diabetes should be advised to perform at least 150 minutes/week of physical activity (50-70% of maximum heart rate). (A)
• In the absence of contraindications, people with type 2 diabetes should be encouraged to perform resistance training
three times per week; targeting all major muscle groups.28 (A)
Moderate-intensity activity for about 150 minutes a week has been shown to substantially lower the risk of heart disease in people with
diabetes.29 For individuals whose goals are weight loss, 300 minutes (5 hours) or more of moderate-intensity activity a week has even
greater benefit.30 Health care providers should work with their patients with diabetes to adapt physical activity so that it is appropriate for
their condition.
Recommendations for screening asymptomatic patients with diabetes for coronary artery disease (CAD) before starting on a program
of physical activity remain unclear. A recent ADA Consensus Statement on this issue concluded that routine screening is not
recommended and providers should use clinical judgment in this area, including encouraging high-risk patients to start with short periods
of low-intensity physical activity and to increase the duration and intensity gradually.31 Providers should also assess patients with diabetes
for conditions that might contraindicate certain types of physical activity or predispose to injury.
Conditions that may contraindicate moderate to vigorous activity include:
• Uncontrolled hypertension
• Peripheral neuropathy (risk for lower extremity injury)
• Severe autonomic neuropathy or hypoglycemia unawareness
• Pre-proliferative or proliferative retinopathy or macular edema (risk for retinal detachment or vitreous hemorrhage)
• Blood glucose concentration ≥ 250 mg/dl with ketones or ≥ 300 mg/dl without ketones
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26Sigal RJ, et al. Physical activity/exercise and type 2 diabetes. Diabetes Care 27:2518-2539, 2004.
27Department of Health and Human Services: Physical activity and health: A report of the Surgeon General. Atlanta, GA, Centers for Disease Control
and Prevention, 1996.
28American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 32 (Supplement 1):S13-S61, 2009.
29Sigal RJ, et al. Physical activity/exercise and type 2 diabetes. Diabetes Care 27:2518-2539, 2004.
30U.S. Department of Agriculture, http://www.mypyramid.gov
31Bax JJ, et al. Screening for coronary artery disease in patients with diabetes. Diabetes Care 30:2729–2736, 2007.
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Goals for Physical Activity
The overall goals of physical activity are to improve glycemic control, maintain a healthy weight, decrease cardiovascular risk, reduce
blood pressure, improve balance to prevent falls, reduce stress, and improve well-being. These goals should address the individual’s
preferred method of becoming more physically active. Aerobic activity should be distributed over at least three days per week with no
more than two days between activities.
For substantial health benefits, adults should aim for:
• 150 minutes per week of moderately intense physical activity, or
• 75 minutes per week of vigorously intense physical activity, or
• Some combination of the two.
For more extensive health benefits, adults should aim for:
• 300 minutes per week of moderately intense physical activity, or
• 150 minutes of vigorously intense physical activity, or
• Some combination of both.32
Resistance Training
Resistance exercise has been shown to improve insulin sensitivity to about the same extent as aerobic exercise.33,34 Studies have shown
that either aerobic or resistance training alone improves glycemic control in type 2 diabetes, but the improvements are greatest with
combined aerobic and resistance training.35
• The goal is three times per week targeting all major muscle groups. Start by identifying a weight that cannot be lifted more
than 8-10 times. Use this weight and gradually increase to three sets of 8-10 repetitions.
• Resistance training is not recommended for people with significant retinopathy due to risk of retinal detachment or
vitreous hemorrhage.
Basic Education
• Relationship of physical activity to change in blood glucose levels
• Impact of physical activity on risk for hypoglycemia (especially in patients taking sulfonylureas, meglitinides, or insulin prepara-
tions). Added carbohydrate should be ingested if pre-exercise glucose is < 100 mg/dl.
• Potential for impact of physical activity on blood glucose levels up to 12-24 hours after completion
• Types of physical activity
• Injury prevention
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32U.S. Department of Health and Human Services. 2008 Physical Activity Guidelines for Americans: http://www.health.gov/paguidelines/guidelines/chapter7.aspx
33Dunstan DW, et al. High-intensity resistance training improves glycemic control in older patients with type 2 diabetes. Diabetes Care 25:1729–1736, 2002.
34Castaneda C, et al. A randomized controlled trial of resistance exercise training to improve glycemic control in older adults with type 2 diabetes.
Diabetes Care 25:2335–2341, 2002.
35Sigal RJ, et al. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes. Annals of Internal Med 147:357–369, 2007.
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The ADA and the European Association for the Study of Diabetes published a consensus statement on the approach to management of
hyperglycemia in individuals with type 2 diabetes. Highlights of this approach are: intervention at the time of diagnosis with metformin in
combination with lifestyle changes (MNT and physical activity), and continuing timely augmentation of therapy with additional agents
(including early initiation of insulin therapy) as a means of achieving and maintaining recommended levels of glycemic control (i.e., A1C
< 7% for most patients). The overall objective is to achieve and maintain glycemic control and to change interventions when therapeutic
goals are not being met.36,37
The U.S. Food and Drug Administration (FDA) has approved many classes of oral agents for monotherapy (see Metabolic Management
of Type 2 Diabetes on page 18 in this document). The choice of a particular agent must depend, however, on the individual’s character-
istics, self-monitoring of blood glucose (SMBG) profiles, clinical scenario, cost-effectiveness, and physician preferences. Before initiating
therapy, renal status and hepatic function should be evaluated. Appropriate nutrition and physical activity should be maintained even if
the diabetes is being managed pharmacologically. This suggested treatment approach reflects current thinking; however, changes will
continue to be made in this recommended algorithm as the science evolves.
In the case of monotherapy not achieving target glycemic goals, combinations of oral agents or injectable therapies should be attempted.
The adverse effect profile of a particular course of therapy may determine which combination regimen is chosen for a specific patient.
Individual concerns over hypoglycemia, gastrointestinal (GI) side effects, or edema may tip the scale away from one permutation towards
another. Cardiac, renal, and hepatic function should be evaluated as appropriate for each oral agent. The table on page 19 compares the
oral antidiabetic agents. Insulin can be used either alone or in combination with an indicated oral/injectable drug regimen.
New drugs to treat diabetes are in development and in various stages of approval by the FDA. Since 2007, the FDA has been concerned
about cardiovascular side effects of diabetes drugs due to increased risk of heart attacks associated with rosiglitazone (Avandia®).38 The
FDA now requires manufacturers to evaluate cardiovascular risks for all new drugs for diabetes before approval. Some new medications,
saxagliptin (Onglyza®) and liraglutide (Victoza®), may not need to meet this requirement, as they were under development prior to the
new regulation.
See Appendix A: Commonly Used Antidiabetic Agents (pages 45-50).
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36American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 32 (Supplement 1):S13-S61, 2009.
37Nathan DM, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy:
a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32:193–203, 2009.
38http://www.fda.gov/cder/drug/InfoSheets/HCP/rosiglitazone200707HCP.htm#2007_5
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At diagnosis:
Lifestyle
+
Metformin
Lifestyle + Metformin
+
Basal Insulin
Lifestyle + Metformin
+
Intensive insulin
Lifestyle + Metformin
+
Sulfonylurea1
Lifestyle + Metformin
+
Pioglitazone
No hypoglycemia
Edema/CHF
Bone loss
Lifestyle + Metformin
+
Pioglitazone
+
Sulfonylurea
Lifestyle + Metformin
+
Basal insulin
Lifestyle + Metformin
+
GLP-1 agonist2
No hypoglycemia
Weight loss
Nausea/vomiting
Tier 1: Well-validated core therapies
Tier 2: Less well-validated therapies
STEP 1 STEP 2 STEP 3
Reinforce lifestyle interventions at every visit and check A1C every 3 months until A1C is < 7%, and then at least every 6 months.
The interventions should be changed if A1C is >_ 7%.
Renal dysfunction is considered a contraindication to metformin use because it may increase the risk of lactic acidosis, an extremely
rare (less than 1 case per 100,000 treated patients) but potentially fatal complication. However, recent studies have suggested that
metformin is safe unless the estimated glomerular filtration rate falls to < 30 ml/min.
1Sulfonylureas other than glyburide or chlorpropamide
2Insufficient clinical use to be confident regarding safety
Adapted from: Nathan D, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy.
Diabetes Care 32:193-203, 2009.
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a Repaglinide more effective in lowering A1C than nateglinide.
39Nathan D, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy.
Diabetes Care 32:193-203, 2009.
INTERVENTION EXPECTED DECREASE IN ADVANTAGES DISADVANTAGES
A1C WITH MONOTHERAPY (%)
TIER 1: WELL-VALIDATED CORE
Step 1: initial therapy
Lifestyle to decrease 1.0–2.0 Broad benefits Insufficient for most within first year
weight and
increase activity
Metformin 1.0–2.0 Weight neutral GI side effects, contraindicated
with renal insufficiency
Step 2: additional therapy
Insulin 1.5–3.5 No dose limit, rapidly One to four injections daily,
effective, improved monitoring, weight gain,
lipid profile hypoglycemia, analogues
are expensive
Sulfonylurea 1.0–2.0 Rapidly effective Weight gain, hypoglycemia
(especially with glibenclamide
or chlorpropamide)
TIER 2: LESS WELL-VALIDATED
TZDs 0.5–1.4 Improved lipid profile Fluid retention, CHF, weight gain,
(pioglitazone), potential bone fractures, expensive,
decrease in Myocardial potential increase in
Infarction (pioglitazone) Myocardial Infarction (rosiglitazone)
GLP-1 agonist 0.5–1.0 Weight loss Two injections daily, frequent
GI side effects, long-term safety
not established, expensive
OTHER THERAPY
a-Glucosidase inhibitor 0.5–0.8 Weight neutral Frequent GI side effects,
three times/day dosing, expensive
Glinide 0.5–1.5a Rapidly effective Weight gain, three times/day
dosing, hypoglycemia, expensive
Pramlintide 0.5–1.0 Weight loss Three injections daily, frequent
GI side effects, long-term
safety not established, expensive
DPP-4 inhibitor 0.5–0.8 Weight neutral Long-term safety not established,
expensive
SUMMARY OF GLUCOSE-LOWERING INTERVENTIONS39
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40Carver C. Insulin treatment and the problem of weight gain in type 2 diabetes. The Diabetes Educator 32:910-917, 2006.
41White Jr. JR. The pharmacological reduction of blood glucose in patients with type 2 diabetes mellitus. Clinical Diabetes 16:1998.
42Cochrane E, et al. The use of U-500 in patients with extreme insulin resistance. Diabetes Care 28:1240-1244, 2005.
43The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuing glucose monitoring and
intensive treatment of type 1 diabetes. NEJM 359:1464-1476, 2008.
DIABETES MEDICATIONS
Insulin Considerations
The use of insulin requires the following considerations:
• The onset, peak, and duration of any insulin preparation may vary depending on injection site, exercise, depth of injection, and other
variables. Hypoglycemia is a side effect of insulin, and patients must be instructed on the risks as well as appropriate treatments for
hypoglycemia.
• Reduced hyperglycemia and an improvement in glucose toxicity will occur in patients with type 2 diabetes, given sufficient doses of
insulin. Individuals with moderately controlled type 2 diabetes, defined as a fasting plasma glucose ≥ 140 and < 200 mg/dl, will often
show sufficient response to a single or twice-daily dose of insulin.
• Insulin therapy often results in weight gain as a result of improved blood glucose utilization. Attention should be given to lifestyle
adjustments, such as modifications to diet and implementing an exercise program, which can counteract insulin-induced weight gain.40
• Individuals with uncontrolled type 2 diabetes, defined as a fasting plasma glucose of ≥ 200 mg/dl, or those who have proved not
responsive to the above-mentioned regimens, may require frequent insulin dosing. This usually requires the addition of short-acting
insulin before meals.
• The total daily insulin doses for type 2 diabetes may range from 0.4 - 1.2 U/kg/day. Be aware that in insulin-resistant patients, doses of
> 1.5 U/kg/day may be required.
• Total daily dosage for people with type 1 diabetes may range from 0.3 - 0.8 U/kg/day.
• The degree of glucose-lowering effect is dose-related. Studies have demonstrated a lowering of fasting glucose of up to 190 mg/dl from
baseline in patients with type 2 diabetes treated with insulin.
• Insulin can be delivered via syringe, pen, or pump.41
Insulins listed in the medications chart in Appendix A are U-100 (100 units per ml). In some cases, U-500 (500 units of insulin per ml)
may be used. This may be an option for patients requiring very high doses of insulin (i.e., ≥ 200 units per day). Using this high-potency
alternative allows injections of smaller volumes, but increases the potential for serious hypoglycemia. Extreme caution in dosing is
advised.42
Continuous Glucose Monitoring Systems (CGMS)
An endocrinologist may be consulted for evaluation and possible use of CGMS in appropriately selected patients. Candidates for CGMS
are patients who have: hypoglycemia unawareness, recurrent hypoglycemia (E), or nocturnal hypoglycemia; who are geriatric or pregnant;
are on pump therapy; or are on insulin and failing treatment.43
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Insulin regimens should be designed taking lifestyle and meal schedule into account. The algorithm can only provide basic guidelines
for initiation and adjustment of insulin.
*Premixed insulins, combining rapid- and longer-acting insulin in a single injection, are not recommended during adjustment of
doses; however, they can be used conveniently, usually before breakfast and/or dinner, if the proportional adjustments of rapid- and
intermediate-acting insulins are the same as the fixed proportions available.
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Initiation and Adjustment of Insulin Regimens44
44Nathan D, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy.
Diabetes Care 32:193-203, 2009.
Start with bedtime intermediate-acting insulin or
bedtime or morning long-acting insulin
(can initiate with 10 units or 0.2 units per kg)
Check fasting glucose (fingerstick) usually daily and increase dose,
typically by 2 units every 3 days until fasting levels are consistently in
target range (70-130 mg/dl). Can increase dose by larger increments,
e.g., by 4 units every 3 days, if fasting glucose is > 180mg/dl
If hypoglycemia occurs, or fasting
glucose level < 70 mg/dl, reduce
bedtime dose by 4 units or 10%,
whichever is greater
No
No
Yes
Yes
Continue regimen;
check A1C every 3
months
Pre-lunch blood glucose out
of range. Add rapid-acting
insulin at breakfast*
Recheck pre-meal blood glucose levels. If out of range, may need to
add another injection. If A1C continues to be out of range, check 2-h
postprandial levels and adjust preprandial rapid-acting insulin
Pre-bed blood glucose
out of range. Add
rapid-acting insulin at
dinner *
Pre-dinner blood glucose
out of range. Add NPH
insulin at breakfast or rapid-
acting at lunch
If fasting blood glucose is in target range (70-130 mg/dl),
check blood glucose before lunch, dinner, and bed.
Depending on blood glucose results, add second injection
as below. Can usually begin with ~ 4 units and adjust by 2
units every 3 days until blood glucose is in target range
A1C ≥ 7% after 2-3 months
A1C ≥ 7% after 3 months
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Summary of Lipid-Lowering Therapy
Diabetes has been classified as a coronary equivalent and patients with diabetes should be treated as if they have underlying cardiovascular
disease (CVD). They are likely to benefit from early intervention with lifestyle modification and cardio-protective drugs, if necessary.
Evidence from clinical trials published over the past decade suggests that broad-based treatment of dyslipidemia, hypertension,
microalbuminuria, and hypercoagulability (as well as interventional cardiology and cardiovascular surgery during acute coronary
syndrome) can improve the event-free survival rate in people with diabetes who already have clinical CVD.45
Recommendations:
• Annual fasting test for lipid disorders. More often if necessary to reach goal levels. (E)
• Testing every two years is adequate for those with low-density lipoprotein (LDL), high-density lipoprotein (HDL), and
triglycerides (TG) within the target levels listed. (E)
• Lifestyle modification focusing on reduction of saturated fat, trans fat, and cholesterol intake; weight loss (if indicated) and increased
physical activity should be recommended to improve lipid profile. (A)
• Statin therapy should be added to lifestyle therapy, regardless of baseline lipid levels, for patients with diabetes with overt CVD (A) and
for patients without CVD who are over the age of 40 and have one or more other CVD risk factors (see Coronary Heart Disease on
page 26). (A)
• In patients without overt CVD and under age 40, or those with multiple CVD risk factors, statin therapy should be considered in
addition to lifestyle therapy if LDL cholesterol remains above 100 mg/dl. (E)
• In individuals without overt CVD, the primary goal is an LDL cholesterol goal of < 100 mg/dl. (A)
• In individuals with overt CVD, a lower LDL cholesterol goal of < 70 mg/dl, using a high dose of a statin, is an option. (B)
• If patients treated with drugs do not reach targets on maximal tolerated statin therapy, a reduction in LDL cholesterol of ~30-40%
from baseline is an alternative therapeutic goal. (A)
• Triglyceride levels < 150 mg/dl and HDL cholesterol > 40 mg/dl in men and > 50 mg/dl in women are desirable. However, LDL
cholesterol-targeted statin therapy remains the preferred strategy. (C)
• Statin therapy is contraindicated in pregnancy. (E)
Lifestyle Modifications
Specific lifestyle changes aimed at improving lipid profiles are recommended for all patients with diabetes. Lifestyle intervention should
include MNT, increased physical activity, smoking cessation, and weight loss, if indicated. MNT should be tailored to the individual
patient and focus on the reduction of saturated fat, cholesterol, and trans fat intake.46
According to the American Dietetic Association’s Evidence Analysis Library, there is fair evidence to support the use of omega-3 fatty acids
in decreasing the risk of death from cardiac events and non-fatal myocardial infarctions (MI). If not contraindicated, omega-3 fatty acids
can be added to the diet. They can be from both marine and plant sources: two 4-oz. servings of fish per week (preferably fatty fish such as
mackerel, salmon, herring, trout, sardines, or tuna) and plant-based foods containing 1.5 g alpha-linolenic acids (1 Tbsp canola or walnut
oil, 0.5 Tbsp ground flax seed, < 1 tsp flax seed oil). The FDA does warn that fatty fish can be high in methylmercury and should be
limited accordingly in women who are or may become pregnant, nursing mothers, and young children.47
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45Remuzzi G, et al. Prevention and treatment of diabetic renal disease in type 2 diabetes: The BENEDICT study. J Am Soc Nephrol 17:S90–S97, 2006.
46Grundy SM, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation
110:237-239, 2004.
47U.S. Food and Drug Administration, Center for Food Safety and Nutrition, http://www.cfsan.fda.gov/~dms/admehg3.html
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Target Levels of Risk Factors in Patients with Diabetes
First priority
LDL cholesterol (mg/dl) Non-HDL cholesterol (mg/dl)
Highest-risk patients, including those with:
diabetes plus one or more additional
major CVD risk factors < 70 < 100
High-risk patients, including those with:
diabetes but no other major CVD risk factors < 100 < 130
Second priority
Triglycerides < 150 mg/dl
HDL cholesterol > 40 mg/dl (male); > 50 mg/dl (female)
Non-HDL cholesterol (total cholesterol minus HDL cholesterol) reflects the concentration of cholesterol within all lipoprotein particles
currently considered atherogenic. The Adult Treatment Panel III (ATP III) proposed that in individuals with hypertriglyceridemia (which
would include many with diabetes), non-HDL cholesterol levels are a secondary goal of therapy after targeting LDL cholesterol levels.
Many studies have demonstrated that non-HDL cholesterol is a better predictor of CVD risk than is LDL cholesterol and this may be
especially true of statin-treated patients. Additional benefits of non-HDL cholesterol measurement are its lack of additional expense in
patients already getting lipid panel measurements and that it can be calculated from nonfasting samples.48
See: LDL Cholesterol-Lowering Decision Tree in Type 2 Diabetes on page 24.
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*Based on randomized studies for type 2 diabetes: may or may not be applicable for type 1 diabetes.
**If unable to achieve LDL < 70 mg/dl, minimal goal should be 30-40% decrease from baseline with maximal tolerated dose of statin or a tolerable
combination regimen.
Age < 40 Age >40
(+) Risk factors
No guidelines currently exist.
Provide medical nutrition
therapy and physical activity to
maintain goal of LDL < 100
1Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-
lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy
experience. European Heart Journal 20:725–741, 1999.
2Ray KK, et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes. Results from PROVE IT-TIMI 22 Trial. J Am Coll
Cardiol 46:1405-1410, 2005.
3Colhoun HM, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS):
multicentre randomised placebo-controlled trial. Lancet. 364(9435):685-96, 2004.
Statin treatment with management
goal of LDL < 100
(for patients with baseline LDL near
100, still consider statin therapy to
decrease by 30-40%1-3)*
(-) Risk factors
Statin therapy
recommended. Goal is LDL < 70
with either statin alone or in combination
with other lipid-lowering medications**
Statin treatment
with goal
of LDL < 100
No overt CVD Overt CVD No overt CVD
LDL Cholesterol-Lowering Decision Tree in Type 2 Diabetes
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Pharmacological Therapy
Statins are the preferred drugs for LDL reduction. Other drugs that lower LDL include nicotinic acid, ezetimibe (18% reduction), bile
acid sequestrants (15-30%), and fibric acid derivatives (fenofibrate and gemfibrozil, 5-20%). Niacin and fibric acid derivatives are used
primarily for TG lowering. Colesevelam (Welchol®), traditionally used as a cholesterol-lowering agent by binding intestinal bile acids,
may be used as add-on therapy in type 2 diabetes. It lowers LDL by ~20% and A1C by ~0.5%. Other bile acid resins lower blood
glucose as well, but colesevelam is better tolerated. Colesevelam may increase triglycerides, so caution is needed if TG level is over 300
mg/dl. Colesevelam should be avoided if TG level is over 500 mg/dl.
Liver function should be evaluated before the start of pharmacotherapy and post initiation, as directed by package insert.
CARDIOVASCULAR RISK-REDUCTION GUIDELINES
Highlighted drugs are available as generic formulations
* All of these statins are available at doses up to 80 mg except for rosuvastatin. For every doubling of the dose above starting dose,
an approximate 6% decrease in LDL cholesterol level can be obtained.51
** Estimated LDL reductions were obtained from U.S. FDA package inserts for each drug.
49Raikou M, et al. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: Results from the Collaborative
Atorvastatin Diabetes Study (CARDS). Diabetologia 50:733-40, 2007.
50Ray KK, et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes. Results from PROVE IT-TIMI 22 Trial. J Am Coll
Cardiol 46:1405-1410, 2005.
51Buse JB, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the
American Diabetes Association. Diabetes Care 30:162-172, 2007.
Current Available Statin Therapies for Lipid Disorders
Generic Name Trade Name® Dose (mg)* LDL % Reduction**
atorvastatin49,50 Lipitor 10-80 29-45%
fluvastatin Lescol 20-80 17-25%
lovastatin Mevacor 10-80 16-29%
pravastatin Pravachol 10-80 16-27%
rosuvastatin Crestor 5-40 33-46%
simvastatin Zocor 5-80 19-36%
CARDIOVASCULAR RISK-REDUCTION GUIDELINES
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Coronary Heart Disease
Cardiovascular risk factors should be assessed at least annually in people with diabetes. For patients without clear or suggestive symptoms
of coronary artery disease, a risk factor-based approach is recommended, evaluating for dyslipidemia, hypertension, smoking, a positive
family history of premature coronary disease, or the presence of micro- or macroalbuminuria. A recent study, however, concluded that the
presence of traditional and emerging cardiac risk factors failed to identify a significant percentage of patients with silent ischemia.52
Recommendations:
• In patients with known CVD: angiotensin-converting enzyme (ACE) inhibitor (C), aspirin (A), and statin therapy (A)
(if not contraindicated) should be used to reduce risk of cardiovascular events.
• In patients > 40 years of age with another cardiovascular risk factor (hypertension, premature family history, dyslipidemia,
microalbuminuria, cardiac autonomic neuropathy, or smoking) aspirin and statin therapy (if not contraindicated) should be
used to reduce the risk of cardiovascular events. (B)
• A beta-blocker, if not contraindicated, should be added for patients with a prior myocardial infarction. (A)
• Screening tests such as a stress electrocardiogram (ECG), and/or stress echocardiography, and/or perfusion imaging may be
beneficial for those with: 1) typical or atypical cardiac symptoms, and/or
2) an abnormal resting electrocardiogram (E)
Other considerations with less clear evidence:
• A risk factor evaluation aimed at stratifying patients by 10-year risk should be considered. (B)
• Metformin is contraindicated in patients with acute or unstable heart failure, however may be used in patients with
stable congestive heart failure (CHF) if renal function is normal. (C)
• In patients with CHF, thiazolidinediones use is contraindicated. (C)
• Use caution in prescribing thiazolidinediones for patients with preexisting edema or heart disease. (E)
Aspirin Therapy in Diabetes
Both men and women with diabetes have a two- to four-fold increased risk of dying from the complications of cardiovascular disease.
Evidence suggests that aspirin therapy should be prescribed as a secondary prevention strategy and, if no contraindications exist, should
also be used as a primary prevention strategy in men and women with diabetes who are at high risk (over age 40 or with other CVD risk
factors). The use of aspirin has not been studied in individuals under the age of 30.53
Aspirin Therapy Recommendations:
• Use aspirin therapy (75-162 mg/day) as a secondary prevention strategy in men and women with diabetes and a history of myocardial
infarction, vascular bypass procedure, stroke or transient ischemic attack, peripheral vascular disease, claudication, and/or angina. (A)
• Use aspirin therapy (75-162 mg/day) as a primary prevention strategy in men and women with type 1 or type 2 diabetes at increased
cardiovascular risk, including those over 40 years of age or who have additional risk factors (family history of CVD, hypertension,
smoking, dyslipidemia, albuminuria). (C)
• People with aspirin allergy, bleeding tendency, recent gastrointestinal bleeding, and clinically active hepatic disease are not candidates
for aspirin therapy. Other antiplatelet agents, such as clopidogrel, may be a reasonable alternative for high-risk patients with
contraindications to aspirin therapy. (B)
• Combination therapy with aspirin (75–162 mg/day) and clopidogrel (75 mg/day) is reasonable for up to a year after an acute coronary
syndrome. (B)
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52Wackers FJ, et al. Detection of ischemia in asymptomatic diabetic subjects. Diabetes Care 27:1954-1961, 2004.
53American Diabetes Association (Position Statement). Aspirin therapy in diabetes. Diabetes Care 27 (Supplement 1):S72-S73, 2004.
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Summary
Hypertension contributes to the development and progression of chronic complications of diabetes. The primary goal of therapy for adults
with diabetes should be to decrease blood pressure to < 130/80 mmHg. Epidemiological analysis of the United Kingdom Prospective Diabetes
Study (UKPDS) showed a continuous relationship between the level of systolic blood pressure and the risk of stroke, diabetes-related deaths,
heart failure, microvascular complications, and vision loss.
Recommendations:
• Patients with diabetes should be treated to a systolic blood pressure (SBP) < 130 mmHg (C) and to a diastolic blood pressure
(DBP) < 80 mmHg. (B)
• Patients with SBP of 130-139 mmHg or DBP of 80-89 mmHg may be given lifestyle therapy alone for a maximum of 3 months and
then, if targets are not achieved, be treated with the addition of pharmacological agents. (E)
• Patients with more severe hypertension (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg) at diagnosis or follow-up should receive prescriptions
for both antihypertensive medication and lifestyle/behavioral changes.54,55 (A)
• All patients with diabetes and hypertension should be treated with ACE inhibitors, or angiotensin II receptor blockers (ARBs).
If one class is not tolerated, the other should be substituted. Add a thiazide diuretic in those with estimated GFR ≥ 30 ml/min per
1.73 m2 or a loop diuretic for those with estimated GFR < 30 ml/min per 1.73 m2 if needed to reach target blood pressure. (C)
• Monitor renal function and serum potassium levels when using ACE inhibitors, ARBs, or diuretics. (E)
• Multiple drug therapy utilizing two or more agents at proper doses is often necessary to reach target levels. (B)
• Clinical trials provide evidence that ACE inhibitors and ARBs have an additional impact on nephropathy and CVD.56 (A)
Refer to the section on Nephropathy (on page 29) and CVD Risk-Reduction (on page 22).
• Beta-blockers should be added for those who have had a recent myocardial infarction (MI) if not contraindicated; caution should be
used in those with hypoglycemia unawareness. (A)
• In pregnant patients with diabetes and chronic hypertension, target blood pressure goals of 110-129/65-79 mmHg are suggested.
ACE inhibitors and ARBs are contraindicated during pregnancy and should be discontinued in women planning pregnancy due to their
teratogenic effects. (E)
• In elderly patients, blood pressure should be lowered gradually.
Benefit of Aggressive Treatment
Control of hypertension has been demonstrated conclusively to reduce the rate and progression of nephropathy and retinopathy, and
to reduce the complications of cerebrovascular disease and cardiovascular disease (CVD). Recent data suggests that the addition of
amlodipine to an ACE inhibitor may be used instead of an ACE inhibitor and thiazide, as some data suggests improved reduction of
cardiovascular outcomes in at-risk patients.57
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54Adler A, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36):
Prospective observational study. BMJ 321:412-419, 2000.
55Chobanian AV, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and
Blood Institute; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Hypertension 42:1206-52, 2003.
56Schrier RW, et al. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial.
Nat Clin Pract Nephrol 3:428–438, 2007.
57Jamerson K, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk-patients. NEJM 359:2417–2428, 2008.
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Lifestyle Modifications
The Dietary Approaches to Stop Hypertension (DASH) diet, which encourages the intake of fruits, vegetables, whole grains, poultry, fish,
and low-fat dairy products, particularly when combined with sodium restriction, has been associated with substantial improvements in
blood pressure.58 Weight loss, increased physical activity, smoking cessation, and prudent reduction of sodium and alcohol should be
major components of treatment of hypertension. A maximum three-month trial of lifestyle/behavioral modification is recommended for
those with a SBP of 130-139 mmHg or a DBP of 80-89 mmHg.
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Treatment Categories
Systolic Diastolic Comment
< 130 mmHg < 80 mmHg Target blood pressure
130-139 mmHg 80-89 mmHg Lifestyle changes alone (maximum 3 months),
then add drug therapy
≥ 140 mmHg ≥ 90 mmHg Lifestyle changes plus drug therapy
58Buse JB, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and
the American Diabetes Association. Diabetes Care 30:162-172, 2007.
59Chobanian AV, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
JAMA 289:2560-2571, 2003.
60Maser RE, et al. Diabetic autonomic neuropathy and cardiovascular risk: The Pittsburgh Epidemiology of Diabetes Complications Study III.
Arch Intern Med 150:1218-1222, 1990.
61The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Consensus statement on the definition of
orthostatic hypotension, pure autonomic failure, and multiple system atrophy. Neurology 46:1470-1471, 1996.
62Arauz-Pacheco C, et al. The treatment of hypertension in adult patients with diabetes. Diabetes Care 25:134-147, 2002.
HYPERTENSION
Blood Pressure Measurement
• Measure blood pressure at every routine visit. Patients with SBP ≥ 130 mmHg or DBP ≥ 80 mmHg require confirmation on a separate
day. (C)
• Measure blood pressure in a seated position, with feet flat on the floor and arm supported at heart level after 5 minutes of rest.59 (A)
• Orthostatic measurement is recommended to identify autonomic neuropathy. (E)
Cardiovascular autonomic neuropathy is common in patients with diabetes and can cause falsely low or high blood pressure readings,
depending on the position of the patient when the blood pressure is taken.60 Blood pressure and pulse should ideally be measured both in
the supine and standing position, leaving two minutes between readings. Two or more determinations in each position should be obtained
using an appropriately sized cuff. If the first two readings differ by more than 5 mmHg, additional readings should be obtained and
averaged. Orthostatic hypotension is defined as a fall in SBP of at least 20 mmHg or a fall in DBP of at least 10 mmHg within three
minutes of standing up.61,62
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Summary
The earliest clinical evidence of nephropathy is microalbuminuria, the appearance of low but abnormal levels of albumin in the urine. A
harbinger of renal failure and cardiovascular complications in diabetes, microalbuminuria is an albumin concentration in the urine that is
greater than normal but is not detectable with common urine dipstick assays for protein.
When to Screen
• Type 2 diabetes: assess urine albumin excretion at diagnosis and yearly thereafter. (E)
• Type 1 diabetes: assess urine albumin excretion after five years of disease duration and yearly thereafter. (E)
• Serum creatinine should be measured annually for the estimation of glomerular filtration rate (GFR) and to stage the level of
chronic kidney disease.63 (E)
Screening Tests
Urine Albumin:Creatinine Ratio
Most authorities recommend the analysis of a spot sample for the albumin-to-creatinine ratio. Additional options, including a 24-hour
urine collection or a timed collection, are rarely necessary for screening but do provide a more complete evaluation. Due to the variability
in albumin excretion, 2 of 3 samples done in a three to six month period should show elevated levels before diagnosing microalbuminuria.
If normal, repeat yearly.
Random spot collection (preferred):
• Normal: < 30 µg/mg creatinine
• Microalbuminuria: 30-299 µg/mg creatinine
• Macroalbuminuria: ≥ 300 µg/mg creatinine
Several factors may elevate the albumin excretion rate. Screening should be postponed in the following situations: strenuous physical
activity within the previous 24 hours, marked hypertension or hyperglycemia, infection, hematuria, fever, or heart failure.
Serum Creatinine
Serum creatinine should be measured annually for the estimation of glomerular filtration rate (GFR) in all adults with diabetes
regardless of the degree of urinary albumin excretion. The serum creatinine alone should not be used as a measure of kidney function
but instead used to estimate GFR and estimate the stage of chronic kidney disease. The use of prediction equations to estimate GFR
from serum creatinine and other variables (age, sex, race, and body size) is recommended by the National Kidney Foundation as a
cost-effective method of diagnosis and stratification of chronic kidney disease. If the GFR is low, check the parathyroid hormone (PTH)
and vitamin D levels to rule out secondary hyperparathyroidism. Consider referral to a physician experienced in the care of diabetic
renal disease when the estimated GFR has fallen to < 60 ml/min per 1.73 m2, or if difficulties occur in the management of hypertension
or hyperkalemia.
29
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Calculation of Glomerular Filtration Rate
Online resource for estimating GFR:
National Kidney Disease Education Program (NKDEP), National Institutes of Health: http://www.nkdep.nih.gov
PDA downloadable resource for GFR: http://nkdep.nih.gov/professionals/gfr_calculators/gfr_application.htm
Stages of Kidney Disease65
30
Cockcroft-Gault Equation64
(140-Age) x Body Weight (kg) x K
10 x Creatinine (mg/dl)
K is a constant
For males, K = 1.39 For females, K = 0.118
64Rigalleau V, et al. Estimation of glomerular filtration rate in diabetic subjects. Diabetes Care 28:838-843, 2005.
65American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 32 (Supplement 1):S13-S61, 2009.
Stage Description GFR
(ml/min per 1.73 m2 body surface area)
1 Kidney damage* with normal or increased GFR ≥ 90
2 Kidney damage* with mildly decreased GFR 60-89
3 Moderately decreased GFR 30-59
4 Severely decreased GFR 15-29
5 Kidney Failure < 15 or dialysis
* Kidney damage is defined as abnormalities on pathologic urine, blood or imaging tests.
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66American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 32 (Supplement 1):S13-S61, 2009.
67Berl T, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Annals of Internal
Medicine 138:542-554, 2003.
Nephropathy and Hypertension
To reduce the risk or slow the progression of nephropathy, optimal glucose and blood pressure control are recommended. Both systolic
and diastolic hypertension markedly accelerate the progression of diabetic nephropathy. Control of hypertension has been demonstrated to
reduce the rate and progression of nephropathy and to reduce the complications of cerebrovascular disease and CVD. Refer also to the
Cardiovascular (page 22) and Hypertension (page 27) sections of these Guidelines.
Pharmacological Therapy
Recommendations:
• For patients with both micro- and macroalbuminuria, either angiotensin-converting enzyme (ACE) inhibitors or Angiotensin II receptor
blockers (ARBs) should be used except during pregnancy. To assess hyperkalemia and acute kidney disease, serum potassium levels and
serum creatinine should be monitored in patients treated with either class of medication. (E)
• Continued assessment of albumin excretion after diagnosis of microalbuminuria and institution of ACE inhibitor or ARB therapy and
blood pressure control is unclear. Continued surveillance can assess both response to therapy and progression of disease. Some suggest
that reducing abnormal albuminuria (≥ 30 mcg/g) to the normal or near-normal range may improve renal and cardiovascular prognosis,
but this approach has not been formally evaluated in prospective trials.66 (E)
Clinical trials reveal the following observations:
• In patients with type 1 diabetes with microalbuminuria and hypertension, ACE inhibitors delay the progression of nephropathy. (A)
• For patients with type 2 diabetes with both hypertension and microalbuminuria, both ACE inhibitors and ARBs delay
the progression to macroalbuminuria. (A)
• In patients with type 2 diabetes who have hypertension, macroalbuminuria, and renal insufficiency, ARBs delay
the progression of nephropathy. (A)
• Dihydropyridine calcium channel blockers (DCCBs) are less likely to slow the progression of nephropathy compared with ACE
inhibitors or ARBs. DCCBs should be used only as an additional therapy in patients already treated with ACE inhibitors or ARBs.67 (A)
• For patients with albuminuria or nephropathy who cannot tolerate ACE inhibitors and/or ARBs, consider using beta-blockers, diuretics,
or non-DCCBs. Non-DCCBs may reduce albuminuria in patients with diabetes, including during pregnancy. (A)
• Due to their teratogenic potential, caution is advised when using either ACE inhibitors or ARBs in women of childbearing age.
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Kidney Disease and Medical Nutrition Therapy
Medicare and other payers provide coverage of MNT for beneficiaries diagnosed with diabetes or renal disease (except for those receiving
dialysis) when provided by a registered dietitian or nutrition professional who meets the provider qualifications. A referral by the beneficia-
ry’s treating physician indicating a diagnosis of diabetes or renal disease is required. Medicare provides coverage for 3 hours of MNT in the
first year and 2 hours in subsequent years.
32
Nutrition Recommendations for People with Diabetes and Kidney Disease
• Protein: 0.8-1.0 g/kg body wt/day. Several small studies suggest that vegetable or soy protein sources may protect kidney function
compared with red meat sources. Reduction of protein intake to 0.8 g/kg body wt/day in the later stages may improve measures
of renal function. Regardless of the level of protein intake, 50% to 75% of the protein should be of high biological value,
derived predominantly from lean poultry, fish, and soy- and vegetable-based proteins.
• Energy: 35 kcal/kg (high in complex carbohydrate), unless patient is obese
• Fat: < 30% of total calories:
o Polyunsaturated fatty acids ≤ 10%
o Fish oil may be useful for IgA nephropathy (12 g/day)
• Cholesterol: < 200 mg/day
• Sodium: 1,000-2,000 mg/day
• Potassium: Individualize based on labs
• Phosphorus: < 12 mg/kg/day
• Calcium: 1,000-1,500 mg/day, not to exceed 2,000 mg
• Vitamins/minerals: Dietary Reference Intakes for B-complex and vitamin C, individualize vitamin D and iron
• Fluid restriction: May be indicated because of the high incidence of edema in nephrotic syndrome
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Diabetic retinopathy is estimated to be the most frequent cause of new cases of blindness among adults aged 20-74 years in the United
States. The prevalence of retinopathy is strongly related to the duration of diabetes. Follow-up from the Diabetes Prevention Program
(DPP) indicated nearly 8% of people with pre-diabetes (IGT and IFG) already had evidence of retinopathy.68 Intensive diabetes
management with the goal of achieving near normal glycemia has been shown to prevent and/or delay the onset of diabetic retinopathy.
High blood pressure is an established risk factor for the development of macular edema and is linked to the presence of proliferative
diabetic retinopathy. Nephropathy is also associated with retinopathy. Patients with diabetic retinopathy or macular edema are often
asymptomatic. Early diagnosis and prompt application of laser photocoagulation surgery is useful in preventing vision loss, but generally
not beneficial in reversing already diminished acuity.69
Screening Recommendations:
• An ophthalmologist or optometrist who is knowledgeable and experienced in diagnosing the presence of diabetic retinopathy and is
aware of its management should perform comprehensive eye exams. (E)
• Adults with type 1 diabetes should have an initial dilated and comprehensive eye examination within 5 years of the diagnosis
of diabetes. (B)
• Adults with type 2 diabetes should have an initial dilated and comprehensive eye examination shortly following the diagnosis
of diabetes. (B)
• Subsequent examinations for patients with type 1 and type 2 diabetes should be repeated annually. A qualified eye care professional may
recommend less frequent exams (i.e., every 2 years).70 (B)
• Examinations will be required more frequently if retinopathy is progressing. (B)
• Women with preexisting diabetes should have a comprehensive eye exam when planning pregnancy and should be counseled on the risk
of development and/or progression of diabetic retinopathy.71 (B)
• Women with diabetes who become pregnant should have a comprehensive eye exam in the first trimester with close follow-up at inter-
vals determined by retinopathy status throughout pregnancy and for one year postpartum. (B)
• Retinal screening is not necessary for women who develop gestational diabetes because these women are not at increased risk for diabetic
retinopathy. (B)
• In general, small doses of aspirin are safe for preventive therapy in patients with retinopathy; when in doubt, consult a diabetic eye
disease specialist. (A)
• Anyone with a change or loss of vision requires prompt referral to an eye care specialist. (A)
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69American Diabetes Association (Position Statement). Retinopathy in diabetes. Diabetes Care 27 (Supplement 1):S84-S87, 2004.
70American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 32 (Supplement 1):S13-S61, 2009.
71Kitzmiller JL, et al. Managing preexisting diabetes for pregnancy. Summary of evidence and consensus recommendations for care.
Diabetes Care 31:1060-1079, 2008.
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Summary
Neuropathy is a disorder of the peripheral nervous system resulting in loss of nerve fibers affecting many bodily functions. There are
several syndromes of diabetic neuropathy, the most common being autonomic neuropathy and distal symmetric polyneuropathy
(DPN). The diabetic neuropathies are heterogeneous with diverse clinical manifestations. Specific treatment for the underlying
nerve damage is currently not available. Improved glycemic control may slow progression but rarely reverses neuronal loss. Effective
symptomatic treatments are available for the manifestations of DPN and autonomic neuropathy. Early recognition and appropriate
management of neuropathy in the patient with diabetes is important for a number of reasons:
• Non-diabetic neuropathies may be present in patients with diabetes and may be treatable.
• A number of treatment options exist for symptomatic diabetic neuropathy.
• Up to 50% of DPN may be asymptomatic and patients are at risk of insensate injury to their feet.
• Autonomic neuropathy may involve every system in the body.
• Cardiovascular autonomic neuropathy causes substantial morbidity and mortality.
Diabetic Autonomic Neuropathy Recommendations:
• Patients with diabetes should be screened for presenting signs and symptoms of diabetic autonomic neuropathy as part of the initial
history and review of systems. (B)
• Screening for signs and symptoms of cardiovascular autonomic neuropathy should be instituted at diagnosis of type 2 diabetes and 5
years after the diagnosis of type 1 diabetes. (E)
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Cardiac
• Resting tachycardia (>100 bpm)
• Exercise intolerance
• Orthostatic hypotension
(a fall in systolic blood pressure > 20 mmHg
or diastolic blood pressure > 10 mmHg upon standing)
Gastrointestinal
• Esophageal enteropathy
• Gastroparesis
• Constipation
• Diarrhea
• Fecal incontinence
Genitourinary Tract
• Recurrent urinary tract infections
• Pyelonephritis
• Incontinence
• Palpable bladder
• Loss of penile erection
• Retrograde ejaculation
• Sexual dysfunction in female
Other Symptoms
• Hyper- or hypohidrosis
(excessive sweating or inability to sweat)
• Impaired neurovascular function
• Hypoglycemia unawareness
Signs and Symptoms of Autonomic Neuropathy
Treatment for Autonomic Neuropathy
The first step towards the goal of slowing the progression of diabetic neuropathies is to achieve and maintain optimal glycemic control.
Improving labile blood glucose values may have an impact on symptoms as well. A number of pharmacological agents are used to treat the
symptoms of autonomic neuropathies such as gastroparesis, bladder dysfunction, and sexual dysfunction. Although they do not change the
underlying pathology of the disease, they may improve the patient’s quality of life.
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Distal symmetric polyneuropathy (DPN)
Foot ulcers and amputations resulting from neuropathy and/or peripheral vascular disease (PVD) are major causes of disability and
morbidity among people with diabetes. The risk of ulcers or amputations is increased in people who have had diabetes for 10 or more
years; are male; have poor glucose control; smoke; or have cardiovascular, retinal, or renal complications. Early recognition of problems
and risk factor management can delay or prevent unfavorable outcomes.72
DPN Recommendations:
• Conduct a comprehensive foot exam at least annually. The exam may take place in the primary care setting and should include a visual
inspection and palpation for pulses as well as a sensory evaluation using a tuning fork or a Semmes-Weinstein monofilament. (B)
See Foot Inspection and Monofilament Guide (pages 37-38).
• Perform a visual foot inspection at every visit for patients who have neuropathy. (E)
• Provide self-care education to all patients, especially those with risk factors such as smoking or prior lower extremity complications. (B)
• Refer patients who have loss of protective sensation and structural abnormalities, or who have a prior history of lower-extremity
complications, to a podiatrist for ongoing preventive care. (C)
• Screen for peripheral artery disease (PAD) by assessing the pedal pulses and evaluating for a history of claudication. Consider obtaining
an ankle-brachial index (ABI), as many patients with PAD are asymptomatic. (C)
• Refer patients with significant claudication or a positive ABI for further vascular assessment. (C)
• Offer a multidisciplinary approach for patients with foot ulcers and high-risk feet. (B)
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72Boulton AJM, et al. Comprehensive Foot Examination and Risk Assessment: A report of the Task Force of the Foot Care Interest Group of the American Diabetes
Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care 31:1679-1685, 2008.
All of the following:
• Intact protective sensation
• Pedal pulses present
• No severe deformity
• No prior foot ulcer
• No amputation
• Smoking
• Peripheral neuropathy with loss of protective sensation
• Altered biomechanics
• Evidence of increased pressure
(hemorrhage under a callus, erythema)
• Bony deformity
• PVD
• History of ulcers or amputation of the other limb
• Severe nail pathology
• Absent pedal pulses
Screening
Low Risk High Risk: associated with an increased risk for amputation
One or more of the following:
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Symptomatic Treatments
• Aim for stable and optimal glycemic control.
• Avoid extreme blood glucose fluctuations.
• Some patients may need pharmacological treatment for pain associated with distal symmetric polyneuropathy (DPN).
36
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Table of drugs to treat symptomatic DPN73
Class Examples Typical doses*
Tricyclic drugs amitriptyline 10-75 mg at bedtime
nortriptyline 25-75 mg at bedtime
imipramine 25-75 mg at bedtime
Anticonvulsants gabapentin 300-1,200 mg t.i.d.
carbamazepine 200-400 mg t.i.d.
pregabalin† 100 mg t.i.d.
5-hydroxytryptamine and
norepinephrine uptake inhibitor duloxetine† 60-120 mg daily
Substance P inhibitor capsaicin cream 0.025-0.075% applied t.i.d. or q.i.d.
*Dose response may vary; initial doses should be low and titrated up.
†Has FDA indication for treatment of painful diabetic neuropathy.
Many agents have efficacy confirmed in published randomized controlled trials. The choices of treatment will depend on contraindications
as well as reimbursement. Doses should be started low and titrated to efficacy. Particular care should be given to adverse effects in the
elderly. Capsaicin is effective but requires up to 4 weeks to show an effect.
Foot Inspection and Monofilament Guide
Assessing for Loss of Protective Sensation
Use of the Semmes-Weinstein monofilament
• Have the patient look away or close his or her eyes.
• Hold the filament perpendicular to the skin.
• Avoiding any ulcers, calluses, or sores, touch the monofilament to the skin until it bends (see picture below). Hold in place for
approximately 1.5 seconds, then gently remove it.
• Randomly test the sites shown on the diagram below.
• Elicit a response from the patient at each site. Lack of sensation at any site may indicate diabetic neuropathy.74
• Non-disposable monofilaments may be cleaned with 1:10 sodium hypochlorite (household bleach) solution if contaminated with
blood or body fluids.
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Tuning fork instructions
• Strike a 128 Hz tuning fork (hard enough to make a noise).
• Place the vibrating tuning fork on the dorsum of the great toe, just proximal to the nail bed.
• With the hand that is not holding the tuning fork, place a finger on the plantar surface of the same toe.
• Have the patient close his or her eyes and inform you when vibration is no longer perceived.
• Gauge the difference between when the patient stops feeling the vibrating tuning fork and when you stop sensing vibration.
Severe sensory loss is indicated when feeling the vibration stops almost immediately.
• If the patient and the examiner stop feeling the vibration at nearly the same moment, vibratory perception is considered normal.
• Intermediate losses can be judged as mild or moderate loss of perception.
• Some clinicians recommend counting how long the patient perceived the vibration and use 10 seconds as the cut-off for
normal perception.
MONOFILAMENT RESOURCES
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Lower Extremity Amputation Program (LEAP)
Bureau of Primary Health Care (BPHC)
1-888-ASK-HRSA (275-4772)
www.hrsa.gov/leap/default.htm
Disposable
North Coast Medical, Inc.
1-800-821-9319
www.ncmedical.com
Durable
$31.95 each
Set of six, assorted sizes: $146.95
Medical Monofilament Manufacturing, LLC
1-508-746-7877
www.medicalmonofilament.com
Disposable
$0.29-$0.39 each
Mid-Delta Home Health and Hospice
1-800-543-9055
www.middelta.com
Durable
$10.00 each
Sammons, Pruss, Rolyan
1-800-558-8633
www.sammonspreston.com
Durable
$29.99 each
Set of five, assorted sizes: $169.95
All monofilaments are 5.07 (10 gm.)
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Summary
Periodontal disease is more common among people with diabetes compared to the general population. Almost one-third of people with
diabetes have severe periodontal disease with loss of attachment of the gums to the teeth measuring 5 millimeters or more. Periodontal dis-
ease progresses more rapidly and is often more aggressive and difficult to treat in people with diabetes than in people without diabetes.
Defined as a bacterially induced chronic inflammatory process, periodontal disease destroys connective tissue and bone supporting the
teeth, leading to tooth loss. Recent research suggests a bidirectional relationship in that people with diabetes are more susceptible to peri-
odontal disease and the presence of periodontal disease can negatively impact glycemic control.
Symptoms of periodontal disease include red, swollen, tender, and bleeding gums; receding gums; evidence of pus upon gum compression;
persistent bad breath; loose permanent teeth; change in bite; or change in the fit of dentures. Most individuals with diabetes do not have
pain with periodontal disease and some may be asymptomatic.
Concurrent risk factors that increase the chances of developing periodontal disease include disease duration; poor metabolic control;
presence of other long-term complications; smoking; plaque; and hormonal variations as in adolescence, pregnancy, and menopause.
Mouth care is often overlooked when managing other issues associated with diabetes.
Recommendations:75
• Conduct an oral exam as part of the yearly comprehensive visit. (E)
• Advise patients of the importance of oral hygiene. (E)
• Promptly refer patients with symptoms of periodontal disease for dental evaluation. (E)
• Encourage patients to receive dental follow-up twice a year, and more often if necessary. (E)
• Encourage patients who smoke to stop. (E)
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75Moore P, et al. Diabetes and oral health promotion: A survey of disease prevention behavior. J Am Dent Assoc 13:1333-1341, 2000.
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Summary
People with diabetes, in particular those with end organ complications of cardiac and renal disease, are at high risk for complications,
hospitalization, and death from influenza and pneumococcal disease.76 Vaccines can greatly reduce the risk of serious complications from
these diseases. In particular, influenza vaccine has been shown to reduce diabetes-related hospital admissions by as much as 79% during flu
epidemics.77 The CDC and the Advisory Committee on Immunization Practices (ACIP) recommend influenza and pneumococcal vac-
cines for all individuals with diabetes.78
Recommendations:
• Annually provide an influenza vaccine to all patients with diabetes ≥ 6 months of age. (C)
• Administer pneumococcal polysaccharide vaccine to all patients with diabetes ≥ 2 years of age. A one-time revaccination is recommend-
ed for individuals ≥ 65 years of age previously immunized when they were < 65 years of age if the vaccine was administered > 5 years
ago.79 Other indications for repeat vaccination include nephrotic syndrome, chronic renal disease, and other immunocompromised
states. (C)
In addition to influenza and pneumococcal vaccines, early vaccination against hepatitis B is indicated in patients likely to progress to
end-stage kidney disease.80 Zoster vaccine was recently recommended by the ACIP to reduce the risk of shingles and its associated pain in
people > 60 years of age.81 Creation of registries to identify patients with diabetes, and implementation of recall and reminder systems, are
effective strategies to improve immunization rates.82
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76American Diabetes Association: Influenza and pneumococcal immunization in diabetes (Position Statement). Diabetes Care 27 (Supplement 1):S111–S113, 2004
77Colquhoun AJ, et al. Effectiveness of influenza vaccine in reducing hospital admissions in people with diabetes. Epidemiol Infect 119:335–341, 1997.
78http://www.cdc.gov/vaccines/recs/
79American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 32 (Supplement 1):S13-S61, 2009.
80Ibid.
81MMWR Recommendations and Reports. Prevention of Herpes Zoster: Recommendations of the Advisory Committee on Immunization Practices (ACIP),
57(05):1-30, June 6, 2008.
82Centers for Disease Control and Prevention. Recommended adult immunization schedule – United States, 2009. MMWR 57(53), 2008.
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Summary
Patients with diabetes who smoke have a heightened risk of morbidity and premature death due to macrovascular complications. Smoking
is also related to the premature development of microvascular disease and may have a role in the development of type 2 diabetes.83
The cardiovascular burden of diabetes, especially in combination with smoking, needs to be effectively communicated to people with
diabetes and to health care providers. There is little evidence that this risk factor is being addressed as consistently and comprehensively as
its importance requires.
Smoking Cessation Recommendations:
• Advise all patients not to smoke. (A)
• Include smoking cessation counseling and other forms of treatment as a routine component of diabetes care.84 (B)
Prevention and cessation of tobacco use is recommended as an important component of state-of-the-art clinical diabetes care.85
All patients should be advised not to smoke and smoking cessation counseling and other forms of treatment should be included as a
routine component of diabetes care. Tobacco dependence is a chronic condition that often requires repeated intervention by a clinician
or team of clinicians and multiple attempts to quit. Many patients relapse several times before quitting for good. Effective treatments exist
that can significantly increase rates of long-term abstinence.86
It is essential that clinicians and health care delivery systems consistently identify and document tobacco use status and treat every tobacco
user seen in a health care setting. Clinicians should offer every patient who uses tobacco at least the brief “5 A’s” treatment shown to be
effective. The “5 A’s” of treating tobacco use and dependence is a useful way of understanding smoking cessation interventions and
organizing the clinical team to intervene with patients who smoke.
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83Willi C, et al. Active smoking and the risk of type 2 diabetes: A systematic review and meta-analysis. JAMA 298(22):2654–2664, 2007.
84American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 32 (Supplement 1):S13–S61, 2009.
85American Diabetes Association (Position Statement). Smoking and diabetes. Diabetes Care 27 (Supplement 1):S74–S75, 2004.
86Clinical Practice Guideline. Treating Tobacco Use and Dependence: 2008 Update. http://www.ahrq.gov/clinic/tobacco/tobaqrg.pdf
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The “5 A’s” model for treating tobacco use and dependence
Ask:
• Identify and document tobacco use status of every patient at every visit.
Advise:
• In a clear, strong and personalized manner, urge every tobacco user to quit.
• Provide reasons why quitting is beneficial for people with diabetes.
Assess:
• For a current smoker, is the patient willing to make a quit attempt at this time?
• For a former smoker, how recently did you quit and are there any challenges to remaining abstinent?
Assist:
• For a patient willing to make a quit attempt, offer medication. Provide or refer for counseling or additional behavioral treatment (see
resources below).
• Acknowledge weight management concerns, and discourage smoking as a tool for weight control.
• Acknowledge the possible presence of depression or other mood disorders. Depression can interfere with successful cessation efforts.
• For a patient unwilling to quit at this time, provide motivational interventions designed to increase future quit attempts.
• For the recent quitter and anyone with remaining challenges, provide relapse prevention.
Arrange:
• All those receiving the previous A’s should receive follow-up.
While coverage will vary by plan, many health insurance plans, including MassHealth, Commonwealth Care, and Medicare, cover all
or some of the cost of FDA-approved prescription and over-the-counter cessation medications. Some plans also provide coverage for
counseling support. Members of any health plan may also be referred to free telephone support available through the QuitWorks fax
referral program.
QuitWorks
QuitWorks is a free, evidence-based smoking cessation referral service that links patients who want to quit smoking to the full range of
tobacco treatment services offered by the Massachusetts Smoker’s Helpline. QuitWorks, www.quitworks.org, was developed by the
Massachusetts Department of Public Health in collaboration with all major health plans in Massachusetts.
• Using a simple enrollment form, a physician, nurse, or other clinician can easily and quickly enroll patients who use tobacco,
regardless of health insurance status.
• Referring providers will receive faxed information on the services each patient selects and, 6 months later, a report on each
patient's quit status.
Resource: The Quick Reference Guide for Clinicians contains strategies and recommendations from the Public Health Service-sponsored
Clinical Practice Guideline. Treating Tobacco Use and Dependence: 2008 Update. http://www.ahrq.gov/clinic/tobacco/tobaqrg.pdf
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Summary
Psychological and socioeconomic issues can impair the individual's or family's ability to carry out diabetes care tasks and therefore
compromise health status. In particular, depression in people with diabetes requires careful management due to its severe impact on
comorbid conditions as well as on the individual’s quality of life. In addition to obtaining a history of previous psychiatric treatment,
clinicians should assess psychosocial status in a timely and efficient manner so that referral for appropriate services can be accomplished.
Stressors such as family issues, insufficient financial or social resources, eating disorders, and cognitive impairment may impact a
patient’s ability to carry out necessary diabetes care tasks.
Recommendations:
• Incorporate psychological screening and treatment into routine care rather than waiting for identification of a specific problem or
deterioration in psychological status. (E)
• Psychosocial screening and follow-up should include, but is not limited to, attitudes about the illness, expectations for medical
management and outcomes, affect/mood, general and diabetes-related quality of life, resources (financial, social, and emotional),
and psychiatric history. (E)
• Screen for psychosocial problems such as depression, anxiety, eating disorders, and cognitive impairment when adherence to the
medical regimen is poor.87 (E)
Depression is known to affect glycemic control and micro/macrovascular complications. In addition, depressive symptoms play a more
important role in mortality among people with diabetes than in those without diabetes. For adults with diabetes, the presence of two or
more coexisting chronic conditions, particularly coronary artery disease, chronic arthritis, and stroke, increase the chances of developing
major depression. Compared to patients with diabetes who are not depressed, people with diabetes and depression require more costly
care. These differences are partly related to non-adherence to medication regimens and worsened self-care skills. Depressive symptoms
impact subsequent physical symptoms of poor glucose control by influencing patients’ ability to adhere to their self-care regimen.
Although the clinician may not feel qualified to treat psychological problems, utilizing the patient-provider relationship as a foundation
for further treatment can increase the likelihood that the patient will accept referral for other services. It is important to establish that
emotional well-being is part of diabetes management.
The following two questions have shown high sensitivity and specificity:
“During the past month, have you often been bothered by feeling down, depressed, or hopeless?”
“During the past month, have you often been bothered by little interest or pleasure in doing things?”88
Treat depression or refer to a mental health specialist for depression treatment.
• Immediately refer to a mental health specialist familiar with diabetes management if self-harm or an eating disorder is suspected.
A referral is also recommended if a problem is suspected to be organic in origin or when cognitive function is impaired.
Resource:
PHQ Screeners: http://www.phqscreeners.com
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Summary
People with diabetes are more likely to be hospitalized and to have longer durations of hospital stay than those without diabetes.
Hyperglycemia in hospitalized patients has been associated with poor outcomes, such as longer length of stay, increased rates of infections,
and in-hospital deaths.89 Interventions to normalize glycemia, however, have yielded inconsistent results. The ADA and the American
Association of Clinical Endocrinologists (AACE) recently issued a joint statement maintaining the need for good glucose management in
the hospital setting with revised glucose targets of 140-180 mg/dl in the ICU setting, and between 100-180 mg/dl for most patients
admitted to general medical-surgical wards.90
Recommendations:
• All hospitalized patients with diabetes should have their diabetes clearly identified in the hospital record. (E)
• All patients with diabetes should have an order for blood glucose monitoring, with results available to all members of the
health care team. (E)
• Scheduled prandial insulin doses should be appropriately timed in relation to meals and should be adjusted to point-of-care
glucose levels. (C)
• For patients being treated with insulin in the ICU setting, target glucose levels between140-180 mg/dl. (A)
• For non-critically ill patients treated with insulin, premeal blood glucose target should be < 140 mg/dl in conjunction with
random blood glucose values < 180 mg/dl, provided these targets can be safely achieved.91 (A)
Insulin infusions effectively decrease blood glucose concentrations in intensive care settings and reduce morbidity and mortality in
surgical intensive care unit patients. Regimens for intensive insulin therapy should utilize general principles expressed throughout the
literature, but should also be modified based on specifics of the individual institution. Regimens should be responsive to factors that may
rapidly affect the risk for hyper- or hypoglycemia such as:
• Changes in enteral/parenteral feeds (content, rate of delivery, temporary or permanent cessation)
• Order for NPO
• Prolonged period outside of ICU
• Changes in intravenous glucose solution content
• Use of steroids or pressors (increasing or decreasing doses)
• Sudden changes in clinical status (sepsis, acute renal failure)
Institutions should prepare for transition from ICU to general areas of the hospital by arranging for follow-up glucose testing after
intravenous insulin is stopped, and planning for follow-up insulin needs (short-acting during transfer and long-acting during subsequent
days). The traditional sliding-scale insulin regimens, when used as monotherapy, have been shown to be ineffective.92
Patients need to be educated that inpatient use of insulin does not commit them to permanent insulin therapy after discharge.
Patients with hyperglycemia as inpatients, but without a previous diagnosis of diabetes, should have follow-up fasting glucose testing
as outpatients.
For the Summary of ADA/AACE Recommendations, see: www.aace.com/pub/pdf/guidelines/InpatientGlycemicControlConsensusStatement.pdf
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89Pomposelli U, et al. Early postoperative glucose control predicts nosocomial infection rate in diabetic patients. Journal of Parenteral and Enteral Nutrition 22:
77-81, 1998.
90Moghissi ES, et al. American Association of Clinical Endocrinologists and American Diabetes Association. Consensus statement on inpatient glycemic control.
Endocr Pract 15, May/June 2009. Published ahead of print.
91Ibid.
92American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 32 (Supplement 1):S13-S61, 2009.
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APPENDIX A: COMMONLY USED ANTIDIABETIC AGENTS
COMMENTS
Regular self-monitoring of blood glucose
should be considered for medication initiation,
adjustments, or additions.
Decreases hepatic glucose production and
increases insulin sensitivity. When used
as monotherapy, does not cause hypo-
glycemia. Take with food to lessen gas-
trointestinal (GI) side effects. Do not use
with impaired renal or hepatic function.
Hold for iodinated contrast study. Start at
500 mg bid or 850 mg qd, increase 500
mg weekly or 850 mg every 2 weeks. Max
2550 mg/day; however, most studies show
little benefit over 2000 mg/day. Start dose
low and titrate slowly to minimize GI
effects. Extended release formulation may
be given once daily. Do not crush.
Monitor Serum Creatinine (SCr) at base-
line and at least yearly, more often if indi-
cated. Discontinue if age greater than 80
or SCr is > 1.5 in males and > 1.4 in
females. Hold if dehydrated or septic;
increases risk of lactic acidosis. Potential
for vitamin B-12 deficiency.
CLASS GENERIC NAME TRADE USUAL
STRENGTH NAME® DOSAGE
metformin
500, 850, 1000 mg
500 mg/5 ml
Glucophage
Riomet
500-1000 mg bid
metformin extended
release (ER)
500, 750, 1000 mg
Glucophage XR
Glumetza
Fortamet
1000-2000 mg
q pm
1000-2500 mg
q pm
May be divided bid
Biguanides
Stimulates pancreatic islet beta cell
insulin release. Start at 5 mg qd or 2.5
mg qd if elderly. The extended release
(ER) formulation may allow for once
daily dosing. For non-ER form, divide
doses > 15 mg/day. Max 40 mg qd.
Do not cut or crush the ER form.
Start at 2.5 to 5 mg qd or 1.25 mg qd
if at risk for hypoglycemia. Max 20 mg
qd. Take with breakfast or first meal.
glipizide
5, 10 mg
glipizide extended
release (ER)
2.5, 5, 10 mg
Glucotrol
Glucotrol XL
5-20 mg
qd to bid
2.5-20 mg
qd
glyburide
1.25, 2.5, 5 mg
Micronase
Diabeta
1.25-20 mg
qd
No advantage over the nonmicronized
products. Start at 1.5-3 mg qd or 0.75
mg qd if at risk for hypoglycemia. Take
with breakfast or first meal.
glyburide
(micronized)
1.5, 3, 6 mg
Glynase
PresTab
0.75-12 mg
qd
Dosage once daily with first main meal.
Start at 1-2 mg po qd. Titrate by 1-2
mg every 1-2 weeks. Max 8 mg qd.
Take with first main meal.
glimepiride
1, 2, 3, 4, 6, 8 mg
Amaryl 1-4 mg
qd
Second-generation
Sulfonylureas
First-generation
Sulfonylureas are
rarely used and are
not included in
this table.
Caution in elderly
patients
Commonly used oral antidiabetic agents
Drug information in the following tables was obtained from pharmaceutical inserts. These tables do not include all the information need-
ed to use medications safely and effectively, and do not reflect individual provider opinions or practices. See full prescribing information in
package inserts.
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COMMENTS
Similar mechanism of action as the
sulfonylureas (insulinotropic). Unlikely
to cause hypoglycemia if given with meals.
Start at 0.5 mg before each meal, double
preprandial dose weekly. Max 4 mg/dose;
16 mg/day. Take 15-30 minutes before a
meal. Skip dose if meal is skipped. Do not
use in combination with sulfonylureas
or other secretagogues.
CLASS GENERIC NAME TRADE USUAL
STRENGTH NAME® DOSAGE
repaglinide
0.5, 1, 2 mg
Prandin 0.5-4 mg
before meals
nateglinide
60, 120 mg
Starlix 60-120 mg
tid
1-30 minutes
before meals
Insulin
Secretagogues
Meglitinides
Increases peripheral and hepatic sensitivi-
ty to insulin. Approved for use as
monotherapy or in combination with
insulin, metformin, or sulfonylureas.
Neither causes hypoglycemia when used as
monotherapy. Start Actos at 15 mg qd.
Start Avandia at 4 mg qd or 2 mg bid.
May increase dose after 12 weeks.
Maximum dose of Actos is 45 mg qd
and Avandia is 8 mg qd. Use with cau-
tion in the presence of hepatic disease.
Monitor baseline transaminase when
initiating therapy, then periodically as
clinically indicated.
Monitor for symptoms and signs of
congestive heart failure at 6 weeks and
3 months. In patients with CHF, thiazo-
lidinediones use is contraindicated.* Use
caution in prescribing thiazolidinediones
for patients with preexisting edema or
heart diseases. It has been suggested that
rosiglitazone may increase the risk of
myocardial infarction. If a glitazone is
used, pioglitazone should be preferred.
May cause anovulatory premenopausal
women to resume ovulation.
Similar mechanism of action as the
sulfonylureas (insulinotropic). Use
with caution in chronic liver disease.
Unlikely to cause hypoglycemia if
given with meals. Should not be added
to regimens of patients who have not
been adequately controlled by glyburide
or other insulin secretagogues. Start
60-120 mg po tid. Skip dose if meal is
skipped. Do not use in combination
with sulfonylureas or other secretagogues.
rosiglitazone
2, 4, 8 mg
Avandia Start 4 mg
pioglitazone
15, 30, 45 mg
Actos 15-45 mg
Thiazolidinediones
(TZD)
Commonly used oral antidiabetic agents (continued)
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Massachusetts Guidelines for Adult Diabetes Care • Revised June 2009
Diabetes Prevention and Control Program Diabetes Guidelines Work Group
47
Commonly used oral antidiabetic agents (continued)
COMMENTS
Delays and decreases absorption of starch
after a meal. Take with first bite of food.
When used as a monotherapy, does not
cause hypoglycemia. Most common side
effects are excessive flatulence, diarrhea,
and abdominal pain. Start 25 mg tid.
Max 100 mg tid. Start dose low and
titrate slowly to minimize GI effects.
Contraindicated in diabetic ketoacidosis
(DKA), inflammatory bowel disease,
colonic ulceration, or partial intestinal
obstruction. If hypoglycemia occurs in
patients who are being treated with
Precose or Glyset, it MUST be treated
with glucose, not sucrose or complex
carbohydrates.
CLASS GENERIC NAME TRADE USUAL
STRENGTH NAME® DOSAGE
acarbose
25, 50, 100 mg
Precose 50-100 mg tid
miglitol
25, 50, 100 mg
Glyset 50-100 mg tid
Alpha-glucosidase
Inhibitors
Inhibits dipeptidyl peptidase-4, slowing
incretin metabolism, increasing insulin
synthesis and release, and decreasing
glucagon levels. Regulates glucose by
affecting the beta cells and alpha cells in
the pancreas. Approved as monotherapy
and as add-on therapy to metformin or
TZDs.
sitagliptin
25, 50, 100 mg
Januvia 100 mg qd
Dipeptidyl
Peptidase-4
(DPP-4)
Inhibitors
1.25/250, 2.5/500,
5/500 mg
2.5/250, 2.5/500,
5/500 mg
500/2, 500/4,
1000/2, 1000/4 mg
500/15, 850/15 mg
4/1, 4/2, 4/4 mg
50/500, 50/1000 mg
Glucovance
Metaglip
Avandamet
ACTOplusmet
Avandaryl
Janumet
1-2 tabs bid
1-2 tabs qd-bid
1-2 tabs bid
1 tab qd-bid
1 tab q am
1 tab bid
Glyburide/
Metformin
Glipizide/
Metformin
Metformin/
Rosiglitazone
Metformin/
Pioglitazone
Rosiglitazone/
Glimepiride
Sitagliptin/
Metformin
Refer to comments on individual drugs.
Medications: Oral Combination
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COMMENTS
Incretin mimetics stimulate insulin
production in response to elevated
blood glucose levels, inhibit post-meal
glucagon release, and slow nutrient
absorption. Adjunct therapy for type
2 patients who have not achieved
adequate glycemic control.When added
to sulfonylurea therapy, a reduction in
the dose of sulfonylurea may be consid-
ered to reduce the risk of hypoglycemia.
Byetta is supplied for subcutaneous (SC)
injection. Starting dose is 5 mcg bid.
Increase to 10 mcg bid in one month if
tolerated. Injected within 60 minutes
before the morning and evening meals.
PRECAUTIONS: Byetta is not a
substitute for insulin in insulin-requiring
patients. Byetta should not be used in
patients with type 1 diabetes or for
the treatment of DKA. The concurrent
use of Byetta with insulin, TZDs,
D-phenylalanine derivatives, meglitinides,
or alpha-glucosidase inhibitors has not
been studied. Not recommended for
use in patients with end-stage renal
disease or severe renal impairment or
in patients with severe gastrointestinal
disease. Byetta slows gastric emptying
and may reduce the absorption of orally
administered drugs. Drugs requiring
food at the time of administration
should be taken with a meal or snack
when Byetta is not administered.
Medications dependent on threshold
concentrations for efficacy, such as
contraceptives and antibiotics, should
be taken at least 1 hour before Byetta
injection.
SIDE EFFECTS: Observe for hypo-
glycemia if prescribed with a sulfonylurea.
Other adverse events associated with
Byetta (vs. placebo) include nausea (44%
vs. 18%), vomiting (13% vs. 4%), and
diarrhea (13% vs. 6%). Cases of acute
pancreatitis have been reported. Inform
patients to discontinue Byetta if they
have persistent severe abdominal pain
with or without vomiting. Do not start
or restart Byetta in patients with a history
of pancreatitis.
CLASS GENERIC NAME TRADE USUAL
STRENGTH NAME® DOSAGE
exenatide injection Byetta 5 mcg-10 mcgIncretin Mimetic
Used in both type 1 and type 2 patients
on insulin. Decreases postprandial
plasma glucose rise, suppresses glucagon
secretion, delays gastric emptying, and
promotes satiety. Used with meals.
Start patients with type 1 diabetes at
15 mcg sc tid and titrate at 15-mcg
increments to a maintenance dose of 30
mcg or 60 mcg as tolerated. Start type 2
patients at 60 mcg sc tid and titrate to 120
mcg tid as tolerated.
pramlintide injection Symlin
Type 1
30-60 mcg
before meals
Type 2
60-120 mcg
before meals
Amylin Analogue
Commonly used injectable antidiabetic agents
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COMMENTS
Regular self-monitoring of blood glucose
should be considered for medication initia-
tion, adjustments, or additions.
Insulins lispro, aspart, and glulisine are
very short-acting products. Both lispro
and aspart are available mixed with
intermediate-acting preparations as
fixed-ratio combinations, which provide
the benefit of rapid and intermediate
action.
All clear insulins. Can mix with NPH.
Do not mix with detemir or glargine.
INSULIN TYPE
Trade name ® ONSET PEAK DURATION
15-30 minutes
10-20 minutes
10-15 minutes
30 minutes-1 hour
1-2 hours
1 hour
0.8-2 hours
(dose dependent)
1-4 (0.8-4.3) hours
1-3 hours
1-1.5 hours
4-5.5 hours
3.5-9.5 hours
No pronounced
peak
3-5 hours
3-5 hours
3-5 hours
6-10 hours
16-24 hours
24 hours
Up to 24 hours
(dose dependent)
Very short-acting
insulin lispro Humalog
(Eli Lilly)
Very short-acting
insulin aspart
NovoLog (Novo
Nordisk)
Very short-acting
insulin glulisine
Apidra (Sanofi-Aventis)
Short-acting
regular insulin
Intermediate-acting
NPH insulin
Long-acting
insulin glargine
Lantus (Aventis)
approved in pediatric
population > 6 years
Insulin detemir
Levemir (Novo
Nordisk) approved in
pediatric population ≥
6 years
Clear insulin. Can mix with NPH.
Do not mix with detemir or glargine.
NPH and regular insulins are also
available as fixed-ratio combinations of
50/50 and 70/30.
Once daily subcutaneous administration
at a consistent time in patients who
require basal (long-acting) insulin
(glargine) or once or twice daily (detemir)
for the control of hyperglycemia. Neither
should be diluted nor mixed with any
other insulin or solution. Neither is
intended for intravenous administration.
Medications: Insulin
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Medications: Insulin
COMMENTS
Regular self-monitoring of blood glucose
should be considered for medication
initiation, adjustments, or additions.
Give within 15 minutes of a meal;
suspension is cloudy, mix gently/
do not shake
Give 30 minutes before meals;
suspension is cloudy, mix gently/
do not shake
Give within 15 minutes of a meal;
suspension is cloudy, mix gently/
do not shake
Give 30 minutes before meals;
suspension is cloudy, mix gently/
do not shake
Give 30 minutes before meals;
suspension is cloudy, mix gently/
do not shake
Give within 15 minutes of a meal;
suspension is cloudy, mix gently/
do not shake
INSULIN TYPE
Trade name ® ONSET PEAK DURATION
Faster than Humulin
70/30
30-60 minutes
10-20 minutes
30-60 minutes
30-60 minutes
Faster than Humulin
50/50
1-6.5 hours
1.5-16 hours
1-4 hours
2-12 hours
2-5.5 hours
0.8-4.8 hours
Up to 24 hours
(similar to
Humulin 70/30)
Effective: 10 to
16 hours
Max: Up to 18
to 24 hours
Effective: 15 to
18 hours
Max: Up to
24 hours
Effective: 10 to
16 hours
Max: Up to 18 to
24 hours
Effective: 10 to
16 hours
Max: Up to 18 to
24 hours
Similar to
Humulin 50/50
Humalog Mix 75/25
(Eli Lilly)
25% insulin lispro/
75% insulin lispro
protamine
Humulin 70/30
(Eli Lilly)
70% NPH/
30% regular
NovoLog Mix 70/30
(Novo Nordisk)
30% insulin aspart/
70% insulin aspart
protamine
Novolin 70/30
(Novo Nordisk)
70% NPH/
30% regular
Humulin 50/50
(Eli Lilly)
50% NPH/
50% regular
Humalog 50/50
(Eli Lilly)
50% NPH/
50% lispro
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Components of the Comprehensive Diabetes Evaluation1
Medical History
51
Depression Screening
• Psychosocial assessment
Laboratory Evaluation
• A1C
• Fasting lipid profile, including total, LDL and HDL cholesterol and triglycerides
• Liver function tests
• Test for microalbuminuria
• Serum creatinine and calculated GFR
• Thyroid-stimulating hormone (TSH)
• Consider screening for celiac disease in type 1 diabetes and as indicated in type 2 diabetes
Referrals
• Eye exam, if indicated
• Family planning for women of reproductive age
• Medical nutrition therapy (MNT)
• Diabetes self-management education (DSME) upon diagnosis and update annually
• Dental exam
• Mental health referral, if indicated
• Age and characteristics of onset of diabetes
(e.g., DKA, routine laboratory evaluation)
• Prior A1C records
• Eating patterns, nutritional status, and weight history
• Diabetes education history
• Review of previous treatment programs
• Current treatment of diabetes, including
medications, meal plan, and results of glucose
monitoring and patient’s use of data
• Physical activity history
• DKA frequency, severity, and cause
• Hypoglycemic episodes
o Any severe hypoglycemia: frequency, severity, and cause
• History of diabetes-related complications
o Microvascular: eye, kidney, nerve (sensory, including history
of foot lesions; autonomic, including sexual dysfunction and
gastroparesis)
o Macrovascular: cardiac, cerebrovascular disease, PAD
• Psychosocial hisory
• Tobacco use
• Pneumococcal immunization
• Last influenza immunization
Physical Examination
• Height, weight, BMI
• Blood pressure determination,
including orthostatic measurements when indicated
• Fundoscopic examination
• Thyroid palpation
• Skin examination
(for acanthosis nigricans and insulin injection sites)
• Neurological/foot examination
• Palpation of dorsalis pedis (DP) and posterior tibial (PT) pulses
• Presence/absence of patellar and Achilles reflexes
• Determination of proprioception, vibration, and
monofilament sensation
• Cardiovascular exam (neck vein distention, resting heart rate,
peripheral pulses, irregular rhythm, S3 for heart failure)
• Pulmonary exam (check for heart failure)
• Abdominal exam (check for enlarged liver or
tenderness due to gallbladder disease, etc.)
1Adapted from: American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 32 (Supplement 1):S13-S61, 2009.
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Disaster Preparations for People with Diabetes
People with diabetes face particular challenges to their health care if there is a disaster. If told to evacuate, it is important for patients to let
people know they have diabetes and any related conditions so they can obtain appropriate care. It is also important to prevent dehydration
by drinking enough fluids, which can be difficult if drinking water is in short supply. In addition, it is helpful for people with diabetes to
keep something containing sugar with them at all times, in case they develop hypoglycemia. To prevent infections, to which people with
diabetes are more susceptible, careful attention should be paid to the feet and getting medical treatment for any wounds. The following list
can be used as a guide for disaster preparation.
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* Check for expiration dates on supplies; disaster kits should be reviewed and replenished at least twice a year.
Source:
Cefalu WT, et al. The Hurricane Katrina aftermath and its impact on diabetes care. Diabetes Care 29:158-160, 2006.
1. Good diabetes education with a special focus on self-management skills and stress management
2. Immunizations, including tetanus, should be up-to-date
3. Keep a waterproof and insulated disaster kit containing the following items:*
a. List of items to pack during an evacuation
i. Glucose testing strips, lancets, and a glucose testing meter
ii. Medications, including insulin
iii. Syringes
iv. Glucose tabs or gel
v. Antibiotic ointments/creams for external use
vi. Glucagon kit
b. A list of contact information for national organizations, such as the American Diabetes Association, available
from their help lines or the Internet
c. Photocopies of relevant medical information, such as lab tests or procedures
d. Up-to-date information on all oral medications and insulin, including formulation and dosing. If possible, have
the prescription number available. Many chain pharmacies throughout the country may be able to refill based
on the prescription number alone.
4. Evacuate early if possible, taking the above items with you
APPENDIX D
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Body Mass Index (kg/m2)
19 20 21 22 23 24 25 26 27 28 29 30 35 40
Height Body Weight
(in.) (lb.)
58 91 96 100 105 110 115 119 124 129 134 138 143 167 191
59 94 99 104 109 114 119 124 128 133 138 143 148 173 198
60 97 102 107 112 118 123 128 133 138 143 148 153 179 204
61 100 106 111 116 122 127 132 137 143 148 153 158 185 211
62 104 109 115 120 126 131 136 142 147 153 158 164 191 218
63 107 113 118 124 130 135 141 146 152 158 163 169 197 225
64 110 116 122 128 134 140 145 151 157 163 169 174 204 232
65 114 120 126 132 138 144 150 156 162 168 174 180 210 240
66 118 124 130 136 142 148 155 161 167 173 179 186 216 247
67 121 127 134 140 146 153 159 166 172 178 185 191 223 255
68 125 131 138 144 151 158 164 171 177 184 190 197 230 262
69 128 135 142 149 155 162 169 176 182 189 196 203 236 270
70 132 139 146 153 160 167 174 181 188 195 202 209 243 278
71 136 143 150 157 165 172 179 186 193 200 208 215 250 286
72 140 147 154 162 169 177 184 191 199 206 213 221 258 294
73 144 151 159 166 174 182 189 197 204 212 219 227 265 302
74 148 155 163 171 179 186 194 202 210 218 225 233 272 311
75 152 160 168 176 184 192 200 208 216 224 232 240 279 319
76 156 164 172 180 189 197 205 213 221 230 238 246 287 328
Classification of Overweight and Obesity by BMI, Waist Circumference,
and Associated Disease Risk*
Disease Risk* Relative to Normal Weight & Waist Circumference
BMI (kg/m2) Obesity Class Men: ≤ 102 cm (≤ 40 in) Men: > 102 cm (> 40 in)
Women: ≤ 88 cm (≤ 35 in) Women: > 88 cm (> 35 in)
Underweight < 18.5
Normal 18.5-24.9
Overweight 25.0-29.9 Increased High
Obesity 30.0-34.9 I High Very High
35.0-39.9 II Very High Very High
Extreme Obesity ≥ 40 III Extremely High Extremely High
*Disease risk for type 2 diabetes, hypertension, and cardiovascular disease.
Source: National Institutes of Health, National Heart, Lung and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of
overweight and obesity in adults, 1998.
Determining Body Mass Index from Height and Weight
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MASSACHUSETTS GUIDELINES FOR ADULT DIABETES CARE
Blood Pressure, Height and Weight
Dilated Eye Exam
Foot Exam
Comprehensive Lower Extremity
Sensory Exam
Dental Exam
Smoking Status
A1C
Fasting/Casual Blood Glucose
Fasting Lipid Profile
Urine Microalbumin/Creatinine
Serum Creatinine
EKG
Thyroid Assessment
Flu
Pneumovax
Review Self-Management Skills
Review Treatment Plan
Review Education Plan
Review Nutrition Plan
Review Physical Activity Plan
Tobacco Use
Psychosocial Adjustment
Sexuality/Impotence/Erectile
Dysfunction
Preconception/Pregnancy
History &
Physical
Labs
Recommended
Immunizations
Self-Management
Counseling
1Type 1: Initial exam after 3-5 years disease duration. Type 2: Initial exam shortly after diagnosis. A qualified eye care professional may
recommend less frequent exams; more frequent exams will be required if retinopathy is progressing.
2Every 3-6 months if patient has high-risk foot conditions.
32x/yr for stable glycemic control. 4x/yr if change in therapy or if not meeting glycemic goals.
4More stringent goals, including a normal A1C of < 6%, can be considered in individual patients and during pregnancy. Less stringent goals
may be appropriate for some patients.
5If values fall in lower risk levels, assessment may be repeated every 2 years.
6Type 1: Initial test after 5 years disease duration and annually thereafter. Type 2: Initial test at diagnosis and annually thereafter.
These Guidelines are intended for community-dwelling adults. The Guidelines are not intended to replace the clinical judgment of health care providers.
FREQUENCY
Every 3-6 months
Annual1
Every 3-6 months
Initial/Annual2
Every 6 months
Ongoing
Every 3-6 months3
As Indicated
Annual5
Initial/Annual6
Annual
Initial
Initial/As Indicated
Every Fall
Recommended
Once
Initial/Ongoing
Initial/Ongoing
Initial/Ongoing
Initial/Ongoing
Initial/Ongoing
Annual/Ongoing
Initial/Ongoing
Annual/Ongoing
Initial/Ongoing
DESCRIPTION/COMMENTS
If BP ≥ 130/80, initiate measures to lower
Refer to ophthalmologist or optometrist
Visual exam w/o shoes and socks every routine
diabetes visit
Teach protective foot behavior if sensation
diminished. Refer to podiatrist if indicated.
See Foot Inspection and Monofilament Guide
Refer to dentist
Check every visit/Encourage smoking cessation
See Tobacco Use and Diabetes
Ideal goal < 7.0% for most patients4
Action required ≥ 7.0%, make changes in regime
Compare lab results with glucose self-monitoring
See Cardiovascular Risk-Reduction Guidelines
If abnormal, recheck x2 in a 3-month period, then
treat if 2 out of 3 collections show elevated levels
Measure annually forestimationofglomerular filtration rate(GFR)
If patient is > 40 years old or DM ≥ 10 years
Thyroid palpation, thyroid function test(s) if indicated
Also revaccination x1 if ≥ 65 and 1st vaccine > 5 years
ago and patient < 65 at the time of 1st vaccine
Check self-monitoring log book, diet, physical activity, and meds
Refer for Diabetes Self-Management Education if indicated
Refer for Medical Nutrition Therapy if indicated
Assess/Prescribe based on patient’s health status
Assess readiness/Counsel on cessation/Refer to QuitWorks
or other tobacco cessation program
Suggest diabetes support group/Counsel/Refer
Discuss diagnostic evaluation and therapeutic options
Need for tight glucose control 3-6 months preconception.
Consider early referral to OB/GYN.
Summary of Diabetes Care
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Visit Frequency: 2x/yr if meeting treatment goals, 4x/yr if not meeting treatment goals
Date Date Date Date Date Date Date Date
1See discussion under CVD, HTN and Nephropathy in Massachusetts Guidelines for
Adult Diabetes Care.
2Initial urinalysis at diagnosis; annual microalbumin thereafter. See discussion under
Nephropathy in Massachusetts Guidelines for Adult Diabetes Care.
3Type 1: initial exam after 3-5 years disease duration. Type 2: initial exam shortly after
diagnosis. A qualified eye care professional may recommend less frequent exams; more
frequent exams will be required if retinopathy is progressing.
4Fasting Lipid Profile every 2 years if values fall in lower risk levels.
5Recommendations for an LDL goal < 70 should be considered for the patient at very high
risk. See Cardiovascular Risk-Reduction Guidelines in Massachusetts Guidelines for Adult
Diabetes Care.
6Comprehensive lower extremity evaluation (LEE) every 3-6 months if patient has high-risk
foot conditions.
7See Immunizations section in Massachusetts Guidelines for Adult Diabetes Care.
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Patient DOB MR#
Provider Height
Date of Visit
Diabetes Medications & Doses
ASA Therapy
ACE inhibitor or ARB, if indicated1
Weight Value
BMI: Goal BMI < 25 kg/m2 Value
BP: Goal < 130/80 Value
A1C every 3-6 months: Target < 7% for most patients Value
Fasting/Casual Glucose: Goal 70-130 ac, < 180 1-2 hrs pc Value
Review Blood Glucose Records  when done
Tobacco Cessation Counseling  when done
Foot Exam  when done
Psychosocial Assessment as needed  when done
Flu Vaccine Date
Microalbumin2 Date
Dilated Eye Exam3 Date
Fasting Lipid Profile
LDL (goal < 100; < 70 if overtCVD)4,5 Value
HDL (men, goal > 40; women, goal > 50) Value
Triglycerides (goal < 150) Value
Creatinine/GFR Date/Value
Comprehensive Lower Extremity Exam6 Date
Diabetes Self-Management Education referral Date
Medical Nutrition Therapy referral Date
Dental Exam (2x/year) Date
Pneumococcal Vaccine7 Date
EKG: if > 40 years and/or DM ≥10 years Date
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The following health promotion materials on diabetes are free of charge and available in bulk quantities.
To order, please complete the order form on the reverse side or visit www.maclearinghouse.com.
Funded by Massachusetts Department of
Public Health
A project of Health Resources in Action
Massachusetts Guidelines for Adult Diabetes
Care laminated summary
For health care professionals only. Laminated wall chart high-
lights essential components of quality diabetes management.
Revised 2009 • 8-1/2"x 11"
English (#DB721)
Diabetes Care Card wallet card
For adults with diabetes. Helps people with diabetes to
maintain records of medical tests and identify personal
goals. Provides space to list medication and contact
information for health care providers.
2-3/4"x4-1/2" • 4-panel
English (#DB720)
Portuguese (#DB731)
Spanish (#DB730)
Control Your Diabetes. For Life. fact sheet
For adults with diabetes. Provides a three-part action
plan. Encourages people with diabetes to know their A1C,
blood pressure, and cholesterol numbers, and manage their
diabetes to reach their target numbers.
8-1/2"x11" • double-sided
English (#DB742)
Portuguese (#DB743)
Spanish (#DB744)
If You Have Diabetes, You Are at High Risk for
Heart Attack & Stroke brochure
For adults with diabetes. Explains the link between diabetes
and heart disease. Encourages people with diabetes to work
with their health care team to set targets and manage the
ABCs of diabetes: A1C, blood pressure, and cholesterol.
Also includes a record form to track the ABCs.
3-1/2"x8" • 3-panel
English (#DB745)
Diabetes Fact Sheets
For adults with diabetes. Set of five bilingual fact sheets
shares information and resources on diabetes management
(What Is Diabetes?; Do I Have Diabetes?; What Can I Do to
Stay Healthy?; Low Blood Sugar, High Blood Sugar, and
Sick Days; What is the Hemoglobin A1c Test?).
8-1/2"x11" • 5 sheets • reproducible • double-sided
English/Spanish (#DB729) limit of 1 set
Diabetes Eye Exam Referral andCommunication
Form 3-part form
For health care professionals only. Allows for documentation
of referral for patients with diabetes to an eye care specialist
for their annual eye exam. Space is provided for the specialist
to document the retinal examination findings and return to the
physician. 3-part form allows physician, patient, and eye care
specialist to maintain records of referral and exam.
8-1/2"x11" • 3-part
English (#DB777)
Diabetes and Your Feet brochure
For adults with diabetes. Provides information about foot
injuries that can be caused by diabetes. Describes symptoms
and provides instructions for preventive foot care.
3-3/4"x8-1/2" • 3-panel
English (downloadable only)
Haitian Creole (#DB708)
Spanish (#DB709)
Diabetes: Are You at Risk? brochure
For health care professionals (for use with patients).
Describes type 1 and type 2 diabetes, risks for diabetes,
and symptoms. Includes space for health care professionals
to record blood glucose screening results and
recommendations for follow-up.
3-3/4"x8-1/2" • 3-panel • reproducible
English (downloadable only)
Chinese (#DB758)
Haitian Creole (#DB702)
Khmer (#DB759)
Vietnamese (#DB761)
Diabetes Can Harm Your Vision brochure
For adults with diabetes. Features two people with diabetes
who encourage the reader to have an annual eye
examination. Presents facts about diabetes and eye disease.
Large type.
3-3/4"x8-1/2" • 4-panel
English (#DB704)
Haitian Creole (#DB705)
Portuguese (#DB757)
Spanish (#DB706)
Know Your Blood Sugar Numbers brochure
For adults with diabetes. Easy-to-read brochure emphasizes
the importance of blood sugar control and describes two
important tests (HbA1c and finger stick blood glucose) that
tell if blood sugar is at a healthy level. A checklist helps
remind people of important tests and services they need.
3-3/4"x8-1/2" • 3-panel
English (#DB726)
Chinese (#DB734)
Khmer (#DB735)
Portuguese (#DB754)
Spanish (#DB727)
Vietnamese (#DB736)
Easy Eating for Busy People brochure
For adults with diabetes. Easy-to-read brochure emphasizes
the importance of a balanced diet in diabetes management.
Describes food groups using examples and demonstrates how
to balance a meal. Includes sample daily menu and additional
tips for diabetes control. Spanish version includes culturally
appropriate photos and foods.
3-3/4"x8-1/2" • 4-panel
English (#DB752)
Spanish (#DB753)
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CLEARINGHOUSE
MASSACHUSETTS HEALTH PROMOTION
Photocopy this form and FAX your order to
617-536-8012
or MAIL your order to: 
Massachusetts Health Promotion Clearinghouse
Health Resources in Action
95 Berkeley Street, Suite 208, Boston, MA 02116
Photocopy additional blank order forms if more than one page is needed.
Please help us to distribute health promotion materials effectively by completing the following survey:
I AM ORDERING THESE MATERIALS FOR
Regional Center for Healthy Communities HMO/MCO school (K-12)
local, state, or federal agency VNA school (professional)
hospital (dept: ________________) nursing home religious organization
private practice elder agency pharmacy
health center multi-service agency fitness organization
police/fire department day care/preschool other: ___________________
item # title language quantity
ship to: (please print)
contact name __________________________________________________title___________________________________
organization __________________________________________________________________________________________
address & room # _____________________________________________________________________________________
please note: deliveries cannot be made to a PO box
city ________________________________________________________ state________________ zip _________________
phone (_____) ___________________ fax (_____) ___________________ e-mail_________________________________
Please add me to your mailing list for future updates of catalog and related free materials
If you are ordering for an upcoming event or other deadline, please indicate date: _______________________________
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